[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Synthes (USA) Products LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":350},{"warningLetters":4,"total":349},[5,30,51,73,94,115,136,153,174,196,216,234,251,271,292,311,329],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},3332,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-05-26T15:00:00Z\">05\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-20T04:00:00Z\">05\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021\">NS Products, Inc.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","New Drug\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wolfe Vaughn and Craig Sheralyn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>NS Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11721 State Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marysville\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98271\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 20, 2021\u003Cbr>\n\u003Cbr>\nRE: 605706\u003C\u002Fp>\n\n\u003Cp>Dear Wolfe Vaughn and Craig Sheralyn:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\u003C\u002Fp>\n\n\u003Cp>The claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On the home page:\u003Cbr>\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\u003C\u002Fp>\n\n\u003Cp>On the “ABOUT FERTILITY” page:\u003Cbr>\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\u003Cbr>\n\u003Cbr>\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\u003C\u002Fp>\n\n\u003Cp>On the “HOW IT WORKS” page:\u003Cbr>\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\u003Cbr>\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\u003Cbr>\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\u003Cbr>\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\u003Cbr>\no “Raspberry Fruit - Relieves impotence . . .”\u003C\u002Fp>\n\n\u003Cp>Your website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cp>On the “CUSTOMER REVIEWS” page:\u003Cbr>\n• “I had a miscarriage in June 2010 &amp; have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May &amp; I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\u003C\u002Fp>\n\n\u003Cp>Your product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003Cbr>\n\u003Cbr>\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. \u003Cem>POM Wonderful LLC\u003C\u002Fem>, 155 F.T.C. 1, 60-61, (2013),&nbsp;\u003Cem>aff’d in relevant part\u003C\u002Fem>, 777 F.3d 478 (D.C. Cir. 2015); \u003Cem>Daniel Chapter One\u003C\u002Fem>, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), \u003Cem>aff’d\u003C\u002Fem>, 405 Fed. Appx. 505 (D.C. Cir. 2010);&nbsp;\u003Cem>Removatron Int'l Corp\u003C\u002Fem>., 111 F.T.C. 206, 297-99 (1988), \u003Cem>aff’d\u003C\u002Fem>, 884 F.2d 1489, 1496 (1stCir. 1989); see also, \u003Cem>FTC v. Direct Mktg. Concepts\u003C\u002Fem>, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), \u003Cem>aff’d\u003C\u002Fem>, 624 F.3d 1 (1st Cir. 2010); \u003Cem>FTC v. Nat'l Urological Group, Inc\u003C\u002Fem>., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), \u003Cem>aff’d\u003C\u002Fem>, 356 Fed. Appx. 358 (11th Cir. 2009); \u003Cem>FTC v. Natural Solution, Inc\u003C\u002Fem>., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act.&nbsp;\u003Cem>See Daniel Chapter One\u003C\u002Fem>, WL 5160000 at *17-19.\u003C\u002Fp>\n\n\u003Cp>The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and\u003Cbr>\nApplied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nWolfe Vaughn and Craig Sheralyn\n\nNS Products, Inc.\n\n11721 State Ave\n\nMarysville, WA 98271\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nMay 20, 2021\n\nRE: 605706\n\nDear Wolfe Vaughn and Craig Sheralyn:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\n\nThe claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn the home page:\n\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\n\nOn the “ABOUT FERTILITY” page:\n\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\n\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\n\nOn the “HOW IT WORKS” page:\n\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\n\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\n\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\n\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\n\no “Raspberry Fruit - Relieves impotence . . .”\n\nYour website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn the “CUSTOMER REVIEWS” page:\n\n• “I had a miscarriage in June 2010 & have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May & I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\n\nYour product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\n\nIn addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60-61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx. 505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297-99 (1988), aff’d, 884 F.2d 1489, 1496 (1stCir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17-19.\n\nThe FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nActing Director\n\nOffice of Compliance\n\nCenter for Food Safety and\n\nApplied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission","NS Products, Inc.","ns-products-inc-605706-05202021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021","2026-10-26T08:09:35.524317+00:00","Warning Letter","Issued","2021-05-26","605706","Dietary Supplements","Wolfe Vaughn and Craig Sheralyn","2026-08-20T03:06:45.755+00:00","2021-05-20",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":18,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":46,"closeout_date":19,"issuing_office":36,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},3201,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2021-08-17T13:20:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-03T04:00:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fproductos-bredy-usa-llc-614241-08032021\">Productos Bredy USA LLC\u003C\u002Fa>","Division of Southwest Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Samuel Tamez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Productos Bredy USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7601 North Loop East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77028-6017\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 3, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nRe: CMS # 614241\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tamez:\u003C\u002Fp>\n\n\u003Cp>On March 11 through March 16, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Productos Bredy USA LLC located at 7601 North Loop East, Houston, TX 77028-6017. We also conducted an initial inspection on September 24, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import, including your FSVP for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Soft Drinks from supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not develop an FSVP for this product, nor any of the products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>While you registered to complete training on FSVP and committed to developing FSVPs at the conclusion of the inspection in 2018, you have not developed an FSVP for any of the products you import. We also have not received a response to the Form FDA 483a issued on March 16, 2021.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including your \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Soft Drinks imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Soft Drink from supplier&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as the other products you import for which you appear to be in violation of Section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that the foods you import are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 1201 Main Street Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 614241 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSamuel Tamez\n\nRecipient Title\n\nPresident and Co-Owner\n\nProductos Bredy USA LLC\n\n7601 North Loop East\n\nHouston, TX 77028-6017\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nAugust 3, 2021\n\nWARNING LETTER\n\nRe: CMS # 614241\n\nDear Mr. Tamez:\n\nOn March 11 through March 16, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Productos Bredy USA LLC located at 7601 North Loop East, Houston, TX 77028-6017. We also conducted an initial inspection on September 24, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import, including your FSVP for (b)(4) Soft Drinks from supplier (b)(4), located in (b)(4). You did not develop an FSVP for this product, nor any of the products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\n\nWhile you registered to complete training on FSVP and committed to developing FSVPs at the conclusion of the inspection in 2018, you have not developed an FSVP for any of the products you import. We also have not received a response to the Form FDA 483a issued on March 16, 2021.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including your (b)(4) Soft Drinks imported from (b)(4), located in (b)(4).\n\n(b)(3)(A)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of (b)(4) Soft Drink from supplier (b)(4), located in (b)(4), as well as the other products you import for which you appear to be in violation of Section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that the foods you import are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 1201 Main Street Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 614241 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nProgram Division Director\n\nDivision of Southwest Imports","Productos Bredy USA LLC","productos-bredy-usa-llc-614241-08032021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fproductos-bredy-usa-llc-614241-08032021","2026-10-26T08:09:44.640523+00:00","2021-08-17","614241","Food & Beverages","Samuel Tamez","2026-08-20T02:41:17.742+00:00","Via Express Delivery","2021-08-03",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},684,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-16T04:00:00Z\">07\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-animal-products-inc-712860-07162025\">Synergy Animal Products, Inc. \u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark A. Hassler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Synergy Animal Products, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1681 Schubert Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bethel\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:synergyanimalproducts@gmail.com\"> synergyanimalproducts@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 16, 2025\u003C\u002Fp>\u003Cp>Re: 712860\u003C\u002Fp>\u003Cp>Dear Mark A. Hassler,\u003C\u002Fp>\u003Cp>This letter concerns your firm’s marketing of adulterated and misbranded animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your facility located at 1681 Schubert Rd, Bethel, PA 19507 from September 5, 2024, through September 10, 2024. After a review of the inspection report, and a subsequent review of your website, synergyanimalproducts.com, we have determined that you are marketing drugs for use in animals. Specifically, your website and product labeling establish that your, Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint products are drugs under section 201(g)(1) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. For the reasons discussed below, these products are unapproved new animal drugs. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes violations related to the FD&amp;C Act’s labeling requirements for drugs. You distribute drugs that are misbranded under section 502(f)(1) of the FD&amp;C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use.\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes violations of the FD&amp;C Act’s drug manufacturer registration and listing requirements. You do not comply with sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] related to drug manufacturer registration and drug listing, and therefore the drugs you distribute are misbranded under section 502(o) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), Parts 210 and 211. Because your methods, facilities or controls for manufacturing, processing, packing or holding drugs do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, [21 U.S.C. § 351(a)(2)(B)].\u003C\u002Fp>\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>We reviewed your September 28, 2024, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Animal Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your website, synergyanimalproducts.com, and your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>• \u003Cstrong>Ex-Cell Countdown 7000\u003C\u002Fstrong>\u003Cbr>o “Ex-cell Countdown 7000 is a broad coverage product that is great when you’re unsure of the problem you are having, as well as stringiness and hard quarters.”\u003Cbr>o From your ‘Most Common Recommendations’ infographic:\u003Cbr> “White or Yellow Chunks”\u003Cbr> “High SCC or No Visible Signs”\u003Cbr> “Stringy or Hard Quarter”\u003Cbr> “Thick Consistency”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Natural Cow Herbal Support\u003C\u002Fstrong>\u003Cbr>o “Use for…high somatic cell count, scours…”\u003Cbr>o “Scours in Calves”\u003Cbr>o “High Somatic Cell”\u003Cbr>o “… because of their anti-septic, anti-inflammatory &amp; antibacterial properties.”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Ex-Cell Somaticare\u003C\u002Fstrong>\u003Cbr>o “Use when problems look clear and watery and\u002For may contain flakes.”\u003Cbr>o “This formula is designed to target problems that look clear and watery and\u002For may contain flakes”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Superior Cow Cream\u003C\u002Fstrong>\u003Cbr>o “… Sore Teats – Flaky Milk – High S.C.C”\u003Cbr>o “…works beneath the skins surface at a deeper level than traditional udder creams.”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Super Cow Udder Mint\u003C\u002Fstrong>\u003Cbr>o “Super Cow Udder Mint is not for every mastitis case. In most cases, Superior Cow Cream will work, but if a case is really bad, you want the stronger Super Cow Udder Mint.”\u003Cbr>o “… Sore Teats – Flaky Milk – High Somatic Cell Count”\u003C\u002Fp>\u003Cp>Because your products are intended to diagnose, cure, mitigate, treat, or prevent disease and\u002For intended to affect the structure or any function of the body of animals, they are drugs within the meaning of section 201(g)(1) of the FD&amp;C Act, [21 U.S.C. § 321 (g)(1)]. These products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. The new animal drugs you market are not approved or index listed by FDA, and therefore they are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act, [21 U.S.C. § 351(a)(5)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Without Adequate Directions for Use\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You distribute drugs that are misbranded under section 502(f)(1) of the FD&amp;C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use. Adequate directions for use include, among other things, statements of all intended uses (indications), routes of administration, and frequency of administration in language understandable by laypersons. 21 CFR 201.5.\u003C\u002Fp>\u003Cp>Your website states: “Q: What are your products used for? A: Our products are a natural support system for dairy animals udder health. Our products are not FDA approved; therefore we cannot make any claims regarding our products’ purpose. It is at the farmers discretion to determine the products use.”\u003C\u002Fp>\u003Cp>Your attempt to avoid making claims about your products’ uses put animals (and the humans who might consume the byproducts of the dairy cows treated with your products) at risk by not giving users adequate directions for safe use of your drugs. You market your products for use by the general public (laypersons)–who do not know the details of your products’ formulations and how to safely use them–unless you provide that information in the product’s labeling. Although your products are unapproved, they are drugs and must therefore bear adequate directions for use, including statements of their intended uses that are understandable by laypersons.\u003C\u002Fp>\u003Cp>For example, with respect to your products’ labeling, (including its labels and the labeling on your website):\u003C\u002Fp>\u003Cp>- \u003Cstrong>Ex-Cell Countdown 7000\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “great when you’re unsure of the problem you are having”,” “stringiness,” and other statements that laypersons may not understand, such as “high S.C.C.”). This product is also missing clear directions on the route of administration.\u003C\u002Fp>\u003Cp>- “\u003Cstrong>Natural Cow Herbal Support\u003C\u002Fstrong>” does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons such as, “High Somatic Cell,” and vague language such as “Irregular milk”).\u003C\u002Fp>\u003Cp>- \u003Cstrong>Ex-Cell Somaticare\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “when problems look clear and watery”) and has no directions indicating how to prepare the product for administration.\u003C\u002Fp>\u003Cp>- \u003Cstrong>Superior Cow Cream\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (“e.g., vague statements such as “Flaky Milk” and terminology not appropriate for laypersons, such as “High S.C.C”) and its labeling contains contradictory directions for frequency of use (1 to 2 fl. oz. after milking for 2 to 5 days as needed, per the label vs. twice a day for 6-10 days, per the labeling on the product’s website at synergyanimalproducts.com).\u003C\u002Fp>\u003Cp>- \u003Cstrong>Super Cow Udder Mint\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons, such as “High Somatic Cell Count,” and vague language such as “Flaky Milk”).\u003C\u002Fp>\u003Cp>During our review, we noted many other products you sell appear to have similar issues. You should review them all to ensure they contain adequate directions for use.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Drug Registration and Listing Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>None of the animal drugs you manufacture are listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the evidence gathered during our inspection, we have determined your firm’s operations are out of compliance with the FD&amp;C Act’s Current Good Manufacturing Practice (CGMP) requirements (section 501(a)(2)(B) of the FD&amp;C Act, [21 U.S.C. § 351(a)(2)(B)]), and the requirements of its implementing regulation for drug products, 21 CFR Parts 210 and 211. Our inspection found that your operations were fundamentally noncompliant with CGMP in that you had no quality unit, had no written procedures applicable to the production and distribution of animal drug products, performed no testing, and kept no records pertaining to the manufacturing of these products.\u003C\u002Fp>\u003Cp>Your failure to manufacture drugs in accordance with CGMP means there is no assurance they meet the safety requirements of the FD&amp;C Act or have the identity and strength, and meet the quality and purity characteristics, which they are represented to possess. Moreover, as you manufacture drugs for use in food-producing animals (dairy cows), your inadequate controls increase the risk that your drugs will inadvertently enter the food supply.\u003C\u002Fp>\u003Cp>During the most recent FDA inspection of your facility, our investigators observed specific CGMP violations, including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1) Failure to establish a quality control unit. (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has no quality unit (QU) or any procedures for the responsibilities of a QU (including\u002Fbut not limited to setting specifications, performing investigations, reviewing complaints, reviewing production records, conducting annual product reviews, and approving or rejecting procedures, components, labeling, and drug products). During the inspection, you stated you did not consider your products to be animal drugs and therefore you did not establish any CGMP procedures. For the reasons discussed earlier in this letter, your products are animal drugs and are therefore subject to the CGMP requirement. A functioning quality unit with approval and rejection authority is a core element of CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>2) Failure to test your drug products for conformance to final specifications. (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>No release testing was conducted on any animal drug products you manufactured and distributed. Testing each batch of drug products for conformance to specifications, including the identity and strength of each active ingredient, is important to ensure your drugs have the quantity of active ingredient you believe is needed to perform as you intend.\u003C\u002Fp>\u003Cp>\u003Cstrong>3) Failure to test your incoming components for identity, purity, strength, and other appropriate quality attributes. (21 CFR 211.84(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not perform specific identity testing for each shipment of each lot of each component you receive and then test each component for conformity with all appropriate written specifications or otherwise establish the reliability of the supplier’s analyses.\u003C\u002Fp>\u003Cp>The quality of the components you use has a direct effect on the quality of the drug products you manufacture, and testing incoming components for identity is an important step in preventing mislabeled components from being used in manufacturing.\u003C\u002Fp>\u003Cp>Additionally, you do not have written procedures pertaining to incoming components or any associated records including, but not limited to: written procedures related to the receiving of containers, closures, and components; the rejection of nonconforming materials; or supplier qualifications\u002Fsupplier quality agreements. You do not maintain copies of your supplier’s test results (i.e. Certificates of Analysis) for each raw material you use. You use raw materials from multiple outside suppliers.\u003C\u002Fp>\u003Cp>\u003Cstrong>4) Failure to establish written procedures for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. (21 CFR 211.67).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, we observed visibly dirty equipment (e.g., your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank) that you use to manufacture your drug products.\u003C\u002Fp>\u003Cp>You do not have any written procedures or records for the cleaning and maintenance of equipment that you use to make animal drugs. This includes, but is not limited to: written procedures for cleaning, equipment cleaning validation studies, clean\u002Fdirty hold time studies, and cleaning logs. You also do not have preventative maintenance procedures and maintenance logs.\u003C\u002Fp>\u003Cp>Properly cleaned and maintained equipment is needed to prevent microbiological contamination or cross-contamination between batches of different drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>5) Failure to establish master production and control records for each drug product. (21 CFR 211.186(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have master production and control records for any of the drugs you produce. These documents are the foundation of manufacturing in compliance with CGMP because they describe and define each drug, its formulation, the containers, closures, and labeling to be used, the manufacturing process to be followed (the equipment and process), and the sampling and testing to be performed, among other things. As of the inspection, you did not have formulas for any of your products in writing or any master records of any type. These master records are a basic CGMP requirement and necessary to ensure consistency between batches of drug product.\u003C\u002Fp>\u003Cp>\u003Cstrong>6) Failure to prepare batch production and control records for each batch of drug product produced. (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not keep any written records (i.e., batch records) to document your manufacturing process.\u003C\u002Fp>\u003Cp>Batch records are critical for a variety of reasons, such as facilitating review of the production process before batch release, performing investigations, and performing recalls. You have no records to establish what lots of what components were used, how much of each component was actually added, or what manufacturing processes were performed, and you would be unable to evaluate the need for a recall if, for example, there was a recall on a lot of one of the components you used.\u003C\u002Fp>\u003Cp>In summary, you violate the FD&amp;C Act’s CGMP requirement by:\u003Cbr>- using untested components from suppliers you did not qualify; (\u003Cstrong>violation 3 above\u003C\u002Fstrong>)\u003Cbr>- to manufacture drugs with no defined process or written formulation (i.e., no master production record); (\u003Cstrong>violation 5 above\u003C\u002Fstrong>)\u003Cbr>- using equipment which we observed to be unclean during our inspection and for which you do not have cleaning procedures; (\u003Cstrong>violation 4 above\u003C\u002Fstrong>)\u003Cbr>- without keeping any written records of what components or equipment you used (i.e., no batch records); (\u003Cstrong>violation 6 above\u003C\u002Fstrong>)\u003Cbr>- without performing any tests to verify the quality of the finished product (e.g., identity and strength of active ingredient); (\u003Cstrong>violation 2 above\u003C\u002Fstrong>)\u003Cbr>- and then released the drugs without the oversight of a quality unit, which should have rejected those drugs for the reasons above. (\u003Cstrong>violation 1 above\u003C\u002Fstrong>)\u003C\u002Fp>\u003Cp>We have considered your response to the Form FDA 483. You acknowledged our concern about the absence of an adequately established quality unit and committed to the establishment of a dedicated QU by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response failed to provide adequate detail and timelines regarding implementation. We are concerned that your complete lack of a quality unit has contributed–and continues to contribute–to a total failure of oversight regarding your CGMP operations. FDA has not received any recent updates from your firm regarding your proposed corrective actions. Additionally, your responses do not consider the need to mitigate any potential risks that may be associated with your CGMP-deficient processes in relation to your distributed products. During the inspection, you acknowledged the conditions cited above generally apply to all drugs you have manufactured since 2017.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and effectiveness of corrective actions and preventive actions. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Conclusion\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review indicates that you are offering for sale unapproved new animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 712860” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Cindy L. Burnsteel, DVM\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc: info@synergyanimalproducts.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nMark A. Hassler\n\nRecipient Title\n\nPresident and CEO\n\nSynergy Animal Products, Inc.\n\n1681 Schubert Rd\n\nBethel, PA 19507\n\nUnited States\n\nsynergyanimalproducts@gmail.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nJuly 16, 2025\nRe: 712860\nDear Mark A. Hassler,\nThis letter concerns your firm’s marketing of adulterated and misbranded animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act).\nThe U.S. Food and Drug Administration (FDA) inspected your facility located at 1681 Schubert Rd, Bethel, PA 19507 from September 5, 2024, through September 10, 2024. After a review of the inspection report, and a subsequent review of your website, synergyanimalproducts.com, we have determined that you are marketing drugs for use in animals. Specifically, your website and product labeling establish that your, Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint products are drugs under section 201(g)(1) of the FD&C Act [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. For the reasons discussed below, these products are unapproved new animal drugs. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nThis Warning Letter also summarizes violations related to the FD&C Act’s labeling requirements for drugs. You distribute drugs that are misbranded under section 502(f)(1) of the FD&C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use.\nThis Warning Letter also summarizes violations of the FD&C Act’s drug manufacturer registration and listing requirements. You do not comply with sections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)] related to drug manufacturer registration and drug listing, and therefore the drugs you distribute are misbranded under section 502(o) of the FD&C Act.\nThis Warning Letter also summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), Parts 210 and 211. Because your methods, facilities or controls for manufacturing, processing, packing or holding drugs do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, [21 U.S.C. § 351(a)(2)(B)].\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\nWe reviewed your September 28, 2024, response to our Form FDA 483 in detail.\nUnapproved New Animal Drug Violations\nExamples of claims FDA observed on your website, synergyanimalproducts.com, and your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\n• Ex-Cell Countdown 7000\no “Ex-cell Countdown 7000 is a broad coverage product that is great when you’re unsure of the problem you are having, as well as stringiness and hard quarters.”\no From your ‘Most Common Recommendations’ infographic:\n “White or Yellow Chunks”\n “High SCC or No Visible Signs”\n “Stringy or Hard Quarter”\n “Thick Consistency”\n• Natural Cow Herbal Support\no “Use for…high somatic cell count, scours…”\no “Scours in Calves”\no “High Somatic Cell”\no “… because of their anti-septic, anti-inflammatory & antibacterial properties.”\n• Ex-Cell Somaticare\no “Use when problems look clear and watery and\u002For may contain flakes.”\no “This formula is designed to target problems that look clear and watery and\u002For may contain flakes”\n• Superior Cow Cream\no “… Sore Teats – Flaky Milk – High S.C.C”\no “…works beneath the skins surface at a deeper level than traditional udder creams.”\n• Super Cow Udder Mint\no “Super Cow Udder Mint is not for every mastitis case. In most cases, Superior Cow Cream will work, but if a case is really bad, you want the stronger Super Cow Udder Mint.”\no “… Sore Teats – Flaky Milk – High Somatic Cell Count”\nBecause your products are intended to diagnose, cure, mitigate, treat, or prevent disease and\u002For intended to affect the structure or any function of the body of animals, they are drugs within the meaning of section 201(g)(1) of the FD&C Act, [21 U.S.C. § 321 (g)(1)]. These products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. The new animal drugs you market are not approved or index listed by FDA, and therefore they are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act, [21 U.S.C. § 351(a)(5)].\nThe introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&C Act, [21 U.S.C. § 331(a)].\nDrugs Without Adequate Directions for Use\nYou distribute drugs that are misbranded under section 502(f)(1) of the FD&C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use. Adequate directions for use include, among other things, statements of all intended uses (indications), routes of administration, and frequency of administration in language understandable by laypersons. 21 CFR 201.5.\nYour website states: “Q: What are your products used for? A: Our products are a natural support system for dairy animals udder health. Our products are not FDA approved; therefore we cannot make any claims regarding our products’ purpose. It is at the farmers discretion to determine the products use.”\nYour attempt to avoid making claims about your products’ uses put animals (and the humans who might consume the byproducts of the dairy cows treated with your products) at risk by not giving users adequate directions for safe use of your drugs. You market your products for use by the general public (laypersons)–who do not know the details of your products’ formulations and how to safely use them–unless you provide that information in the product’s labeling. Although your products are unapproved, they are drugs and must therefore bear adequate directions for use, including statements of their intended uses that are understandable by laypersons.\nFor example, with respect to your products’ labeling, (including its labels and the labeling on your website):\n- Ex-Cell Countdown 7000 does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “great when you’re unsure of the problem you are having”,” “stringiness,” and other statements that laypersons may not understand, such as “high S.C.C.”). This product is also missing clear directions on the route of administration.\n- “Natural Cow Herbal Support” does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons such as, “High Somatic Cell,” and vague language such as “Irregular milk”).\n- Ex-Cell Somaticare does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “when problems look clear and watery”) and has no directions indicating how to prepare the product for administration.\n- Superior Cow Cream does not have a clear indication statement that is understandable by laypersons (“e.g., vague statements such as “Flaky Milk” and terminology not appropriate for laypersons, such as “High S.C.C”) and its labeling contains contradictory directions for frequency of use (1 to 2 fl. oz. after milking for 2 to 5 days as needed, per the label vs. twice a day for 6-10 days, per the labeling on the product’s website at synergyanimalproducts.com).\n- Super Cow Udder Mint does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons, such as “High Somatic Cell Count,” and vague language such as “Flaky Milk”).\nDuring our review, we noted many other products you sell appear to have similar issues. You should review them all to ensure they contain adequate directions for use.\nDrug Registration and Listing Violations\nSections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&C Act.\nNone of the animal drugs you manufacture are listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act.\nCurrent Good Manufacturing Practice Violations\nBased on the evidence gathered during our inspection, we have determined your firm’s operations are out of compliance with the FD&C Act’s Current Good Manufacturing Practice (CGMP) requirements (section 501(a)(2)(B) of the FD&C Act, [21 U.S.C. § 351(a)(2)(B)]), and the requirements of its implementing regulation for drug products, 21 CFR Parts 210 and 211. Our inspection found that your operations were fundamentally noncompliant with CGMP in that you had no quality unit, had no written procedures applicable to the production and distribution of animal drug products, performed no testing, and kept no records pertaining to the manufacturing of these products.\nYour failure to manufacture drugs in accordance with CGMP means there is no assurance they meet the safety requirements of the FD&C Act or have the identity and strength, and meet the quality and purity characteristics, which they are represented to possess. Moreover, as you manufacture drugs for use in food-producing animals (dairy cows), your inadequate controls increase the risk that your drugs will inadvertently enter the food supply.\nDuring the most recent FDA inspection of your facility, our investigators observed specific CGMP violations, including, but not limited to, the following:\n1) Failure to establish a quality control unit. (21 CFR 211.22).\nYour firm has no quality unit (QU) or any procedures for the responsibilities of a QU (including\u002Fbut not limited to setting specifications, performing investigations, reviewing complaints, reviewing production records, conducting annual product reviews, and approving or rejecting procedures, components, labeling, and drug products). During the inspection, you stated you did not consider your products to be animal drugs and therefore you did not establish any CGMP procedures. For the reasons discussed earlier in this letter, your products are animal drugs and are therefore subject to the CGMP requirement. A functioning quality unit with approval and rejection authority is a core element of CGMP.\n2) Failure to test your drug products for conformance to final specifications. (21 CFR 211.165(a)).\nNo release testing was conducted on any animal drug products you manufactured and distributed. Testing each batch of drug products for conformance to specifications, including the identity and strength of each active ingredient, is important to ensure your drugs have the quantity of active ingredient you believe is needed to perform as you intend.\n3) Failure to test your incoming components for identity, purity, strength, and other appropriate quality attributes. (21 CFR 211.84(d)).\nYou do not perform specific identity testing for each shipment of each lot of each component you receive and then test each component for conformity with all appropriate written specifications or otherwise establish the reliability of the supplier’s analyses.\nThe quality of the components you use has a direct effect on the quality of the drug products you manufacture, and testing incoming components for identity is an important step in preventing mislabeled components from being used in manufacturing.\nAdditionally, you do not have written procedures pertaining to incoming components or any associated records including, but not limited to: written procedures related to the receiving of containers, closures, and components; the rejection of nonconforming materials; or supplier qualifications\u002Fsupplier quality agreements. You do not maintain copies of your supplier’s test results (i.e. Certificates of Analysis) for each raw material you use. You use raw materials from multiple outside suppliers.\n4) Failure to establish written procedures for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. (21 CFR 211.67).\nDuring the inspection, we observed visibly dirty equipment (e.g., your (b)(4) tank) that you use to manufacture your drug products.\nYou do not have any written procedures or records for the cleaning and maintenance of equipment that you use to make animal drugs. This includes, but is not limited to: written procedures for cleaning, equipment cleaning validation studies, clean\u002Fdirty hold time studies, and cleaning logs. You also do not have preventative maintenance procedures and maintenance logs.\nProperly cleaned and maintained equipment is needed to prevent microbiological contamination or cross-contamination between batches of different drugs.\n5) Failure to establish master production and control records for each drug product. (21 CFR 211.186(a)).\nYou do not have master production and control records for any of the drugs you produce. These documents are the foundation of manufacturing in compliance with CGMP because they describe and define each drug, its formulation, the containers, closures, and labeling to be used, the manufacturing process to be followed (the equipment and process), and the sampling and testing to be performed, among other things. As of the inspection, you did not have formulas for any of your products in writing or any master records of any type. These master records are a basic CGMP requirement and necessary to ensure consistency between batches of drug product.\n6) Failure to prepare batch production and control records for each batch of drug product produced. (21 CFR 211.188).\nYou do not keep any written records (i.e., batch records) to document your manufacturing process.\nBatch records are critical for a variety of reasons, such as facilitating review of the production process before batch release, performing investigations, and performing recalls. You have no records to establish what lots of what components were used, how much of each component was actually added, or what manufacturing processes were performed, and you would be unable to evaluate the need for a recall if, for example, there was a recall on a lot of one of the components you used.\nIn summary, you violate the FD&C Act’s CGMP requirement by:\n- using untested components from suppliers you did not qualify; (violation 3 above)\n- to manufacture drugs with no defined process or written formulation (i.e., no master production record); (violation 5 above)\n- using equipment which we observed to be unclean during our inspection and for which you do not have cleaning procedures; (violation 4 above)\n- without keeping any written records of what components or equipment you used (i.e., no batch records); (violation 6 above)\n- without performing any tests to verify the quality of the finished product (e.g., identity and strength of active ingredient); (violation 2 above)\n- and then released the drugs without the oversight of a quality unit, which should have rejected those drugs for the reasons above. (violation 1 above)\nWe have considered your response to the Form FDA 483. You acknowledged our concern about the absence of an adequately established quality unit and committed to the establishment of a dedicated QU by (b)(4). However, your response failed to provide adequate detail and timelines regarding implementation. We are concerned that your complete lack of a quality unit has contributed–and continues to contribute–to a total failure of oversight regarding your CGMP operations. FDA has not received any recent updates from your firm regarding your proposed corrective actions. Additionally, your responses do not consider the need to mitigate any potential risks that may be associated with your CGMP-deficient processes in relation to your distributed products. During the inspection, you acknowledged the conditions cited above generally apply to all drugs you have manufactured since 2017.\nCGMP Consultant Recommended\nBased on the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and effectiveness of corrective actions and preventive actions. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review indicates that you are offering for sale unapproved new animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 712860” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nCindy L. Burnsteel, DVM\nActing Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc: info@synergyanimalproducts.com","Synergy Animal Products, Inc.","synergy-animal-products-inc-712860-07162025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-animal-products-inc-712860-07162025","2026-10-26T08:10:09.096269+00:00","2025-09-02","712860","Animal & Veterinary","Mark A. Hassler","2026-08-19T16:27:37.151+00:00","Via Email","2025-07-16",{"id":74,"raw":75,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":84,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":19,"issuing_office":57,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},8,[76,77,78,57,79,13,13,13],"\u003Ctime datetime=\"2026-07-28T04:00:00Z\">07\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-12T04:00:00Z\">06\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026\">AHC Products, Inc. \u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Wolf\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Compliance Manager and Pharmacist in Charge \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AHC Products, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 W Broadway St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Winchester\u003C\u002Fspan>, \u003Cspan>KY\u003C\u002Fspan> \u003Cspan>40391-1915\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 12, 2026\u003C\u002Fp>\u003Cp>CMS Case: 728604\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Wolf:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B)].\u003C\u002Fp>\u003Cp>In addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act). The specific products include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, AniPrin P, and Rot-B-Gone.\u003C\u002Fp>\u003Cp>\u003Cstrong>Current Good Manufacturing Practice Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\u003C\u002Fp>\u003Cp>Our review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\u003C\u002Fp>\u003Cp>In your response, you stated that for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the methodology utilized for product release was color comparison to the original \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, and you referenced a scientific publication suggesting that \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a \u003Cstrong>(b)(4)\u003C\u002Fstrong> methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\u003C\u002Fp>\u003Cp>Regarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\u003C\u002Fp>\u003Cp>Your response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> method for determining \u003Cstrong>(b)(4)\u003C\u002Fstrong> values in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is an entirely different matrix, application, and analytical purpose than your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and cannot be relied upon to determine a quantitative value for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fp>\u003Cp>Related to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\u003C\u002Fp>\u003Cp>You are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\u003C\u002Fp>\u003Cp>Moreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\u003C\u002Fp>\u003Cp>Release testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Procedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure that components were suitable for use in the manufacturing of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> or the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Adequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\u003C\u002Fp>\u003Cp>Your response stated that you sent samples of the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\u003C\u002Fp>\u003Cp>Your response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>, providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality;\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data);\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to qualify the equipment and to validate the processes used to manufacture your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product batches, prior to their use in commercial production.\u003C\u002Fp>\u003Cp>Multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\u003C\u002Fp>\u003Cp>Process validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\u003C\u002Fp>\u003Cp>You responded that you are investigating the initiation of the manufacturing process of the finished product \u003Cstrong>(b)(4)\u003C\u002Fstrong> without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced since August were tested by ICP-MS to determine the concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material.\u003C\u002Fp>\u003Cp>Regarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (ID \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, you indicated that as part of the qualification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to measure the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was purchased to determine the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and a certified thermistor to confirm the temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated that SOP PRO-0002.4 Process Change Control will be revised.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\u003C\u002Fp>\u003Cp>The equipment qualification plan included in the response is incomplete. While you state that you have purchased a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\u003C\u002Fp>\u003Cp>The response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\u003C\u002Fp>\u003Cp>The response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\u003C\u002Fp>\u003Cp>The ICP-MS results you provided show significant variability, with \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentrations ranging from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% across the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots tested, representing more than \u003Cstrong>(b)(4) \u003C\u002Fstrong>fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (equivalent to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% available \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You manufactured and distributed multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that did not bear an expiration date in the product label.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Furthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (2) AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\u003C\u002Fp>\u003Cp>Stability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\u003C\u002Fp>\u003Cp>Regarding the lack of stability testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your response states that at such time as you are able to establish appropriate testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> months, depending on the testing).\u003C\u002Fp>\u003Cp>Regarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the date the missed \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample was required to be tested should be \u003Cstrong>(b)(4)\u003C\u002Fstrong>, not \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and that the stability samples for this lot were pulled prior to the previous FDA inspection.\u003C\u002Fp>\u003Cp>You indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\u003C\u002Fp>\u003Cp>Your response is inadequate. The response does not address the lack of expiration dates on distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\u003C\u002Fp>\u003Cp>The requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\u003C\u002Fp>\u003Cp>Expiration dating must be based on adequate stability data generated under appropriate storage.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>The current expiry date for your finished drug products.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Animal Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>\"\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>AniPrin P\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“Aids in relieving minor muscle and joint pain.”\u003C\u002Fli>\u003Cli>“…an aid in reducing fever”\u003C\u002Fli>\u003Cli>“…relief of minor muscle aches… pains in horses.”\u003C\u002Fli>\u003Cli>“…Reproductive Harm…”\u003C\u002Fli>\u003Cli>“...analgesic”\u003C\u002Fli>\u003Cli>“...antipyretic”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Rot-B-Gone\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“...If redness, irritation,..swelling persist, discontinue use.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>You must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See also, 21 CFR 211.137.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Wolf\n\nRecipient Title\n\nCompliance Manager and Pharmacist in Charge\n\nAHC Products, Inc.\n\n301 W Broadway St\n\nWinchester, KY 40391-1915\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJune 12, 2026\nCMS Case: 728604\nWARNING LETTER\nDear Mr. Wolf:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\nThis warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)].\nIn addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act). The specific products include (b)(4), AniPrin P, and Rot-B-Gone.\nCurrent Good Manufacturing Practice Violations\nWe reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\nOur review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm manufactures drug products, including (b)(4) wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released (b)(4) lots of (b)(4) without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of (b)(4) properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\nIn your response, you stated that for (b)(4), the methodology utilized for product release was color comparison to the original (b)(4) product, and you referenced a scientific publication suggesting that (b)(4) concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a (b)(4) methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately (b)(4)% of the (b)(4) raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\nRegarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\nYour response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a (b)(4) method for determining (b)(4) values in (b)(4), which is an entirely different matrix, application, and analytical purpose than your (b)(4) product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the (b)(4) and cannot be relied upon to determine a quantitative value for (b)(4).\"\nRelated to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\nYou are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\nMoreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\nRelease testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nProcedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\nYour firm failed to ensure that components were suitable for use in the manufacturing of your (b)(4) product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient (b)(4) or the inactive ingredients (b)(4).\nAdequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\nYour response stated that you sent samples of the active ingredient (b)(4) along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately (b)(4)% of the (b)(4) raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the (b)(4) raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\nYour response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients (b)(4), providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\no an assessment of all materials to determine whether they are consistently of acceptable quality;\no a review to ensure assigned expiration or retest dates are appropriate (supported by data);\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nThe firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to qualify the equipment and to validate the processes used to manufacture your (b)(4) product batches, prior to their use in commercial production.\nMultiple lots of (b)(4), a (b)(4) agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\nProcess validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\nYou responded that you are investigating the initiation of the manufacturing process of the finished product (b)(4) without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, (b)(4) lots of (b)(4) produced since August were tested by ICP-MS to determine the concentration of (b)(4). Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately (b)(4)% of the (b)(4) raw material.\nRegarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the (b)(4) (ID (b)(4)). Additionally, you indicated that as part of the qualification of the (b)(4), a (b)(4) to measure the rate of (b)(4) was purchased to determine the rate of (b)(4), and a certified thermistor to confirm the temperature of (b)(4). You stated that SOP PRO-0002.4 Process Change Control will be revised.\nYour response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\nThe equipment qualification plan included in the response is incomplete. While you state that you have purchased a (b)(4) and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\nThe response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\nThe response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\nThe ICP-MS results you provided show significant variability, with (b)(4) concentrations ranging from (b)(4)% across the (b)(4) lots tested, representing more than (b)(4) fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of (b)(4) (equivalent to (b)(4)% available (b)(4)). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\nIn response to this letter, provide:\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\n4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\nYour firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for (b)(4). You manufactured and distributed multiple lots of (b)(4) that did not bear an expiration date in the product label.1\nFurthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4); and (2) AniPrin LQ 12% Regular Gallon, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4). This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\nStability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\nRegarding the lack of stability testing for (b)(4), your response states that at such time as you are able to establish appropriate testing of the (b)(4) content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., (b)(4) months, depending on the testing).\nRegarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot (b)(4), the date the missed (b)(4) sample was required to be tested should be (b)(4), not (b)(4), and that the stability samples for this lot were pulled prior to the previous FDA inspection.\nYou indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot (b)(4), you stated that a (b)(4) stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\nYour response is inadequate. The response does not address the lack of expiration dates on distributed (b)(4) products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\nThe requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\nExpiration dating must be based on adequate stability data generated under appropriate storage.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each (b)(4) to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program.\nThe current expiry date for your finished drug products.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\nUnapproved New Animal Drug Violations\nBased on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nExamples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\n(b)(4)\n\"(b)(4).\"\nAniPrin P\n“Aids in relieving minor muscle and joint pain.”\n“…an aid in reducing fever”\n“…relief of minor muscle aches… pains in horses.”\n“…Reproductive Harm…”\n“...analgesic”\n“...antipyretic”\nRot-B-Gone\n“...If redness, irritation,..swelling persist, discontinue use.”\nYour products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nYou must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\nSincerely,\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Director\nDivision of Drug Compliance\nOffice Surveillance and Compliance\nCenter for Veterinary Medicine\n___________________\n1 See also, 21 CFR 211.137.\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","AHC Products, Inc.","ahc-products-inc-728604-06122026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026","2026-10-26T08:07:51.4831+00:00","2026-07-28","728604","Animal & VeterinaryDrugs","Mr. Michael Wolf","2026-08-19T04:27:41.535+00:00","VIA Electronic Mail","2026-06-12",{"id":95,"raw":96,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":84,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":110,"closeout_date":19,"issuing_office":100,"recipient_name":111,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":109,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},145,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2026-05-26T04:00:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026\">GSC Products, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>729653\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wayne Perry\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GSC Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1441 Van Patten Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Duanesburg\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12056-2522\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Wayne Perry:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 331(a).\u003C\u002Fp>\u003Cp>This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Based on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cstrong>Drug Facts . . . Purpose\u003C\u002Fstrong>…Relieves pain and nausea…Relieves pain &amp; inflammation…Increases circulation . . . \u003Cstrong>Uses\u003C\u002Fstrong>: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\u003C\u002Fp>\u003Cp>“Powerful &amp; Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\u003Cbr>https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\u003C\u002Fp>\u003Cp>Your SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\u003C\u002Fp>\u003Cp>In addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\u003C\u002Fp>\u003Cp>Furthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\u003C\u002Fp>\u003Cp>Thus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nReference #:\n\n729653\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nWayne Perry\n\nRecipient Title\n\nFounder and President\n\nGSC Products, LLC\n\n1441 Van Patten Rd\n\nDuanesburg, NY 12056-2522\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nMay 18, 2026\nWARNING LETTER\nTo Wayne Perry:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&C Act, 21 U.S.C. 331(d) and 331(a).\nThis review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nUnapproved New Drug Violations\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nBased on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\n“Drug Facts . . . Purpose…Relieves pain and nausea…Relieves pain & inflammation…Increases circulation . . . Uses: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\n“Powerful & Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\nhttps:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\n“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\nBased on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).1 However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\nYour SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\nIn addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\nFurthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\nThus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.2 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\nThe introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________\n1 M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","GSC Products, LLC","gsc-products-llc-729653-05182026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026","2026-10-26T08:08:50.940349+00:00","2026-05-26","729653","Drugs Over-the-Counter Drugs","Wayne Perry","2026-08-19T04:39:54.735+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2026-05-18",{"id":116,"raw":117,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":63,"fei_number":19,"letter_url":127,"updated_at":128,"action_type":22,"case_status":23,"posted_date":129,"marcs_cms_no":130,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":19,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":134,"action_taken_date":135,"medical_device_id":19,"response_letter_date":19},546,[118,119,120,121,122,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025\">LBC Products Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501315\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>LBC Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6360 South Pecos Road, Suite 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lehab@lbcproducts.com\"> lehab@lbcproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501315, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501315\n\nProduct:\n\nTobacco\n\nRecipient:\n\nLBC Products Inc.\n\n6360 South Pecos Road, Suite 8\n\nLas Vegas, NV 89120\n\nUnited States\n\nlehab@lbcproducts.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 2, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501315, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","LBC Products Inc.","lbc-products-inc-717608-10022025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025","2026-10-26T08:09:12.826898+00:00","2025-10-07","717608","Tobacco","2026-08-19T16:14:50.902+00:00","VIA UPS and Electronic Mail","ER2501315","2025-10-02",{"id":137,"raw":138,"subject":122,"body_html":142,"body_text":143,"firm_name":144,"letter_id":145,"created_at":146,"fei_number":19,"letter_url":147,"updated_at":148,"action_type":22,"case_status":23,"posted_date":149,"marcs_cms_no":150,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":19,"body_fetched_at":151,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":152,"medical_device_id":19,"response_letter_date":19},2514,[139,140,141,121,122,13,13,13],"\u003Ctime datetime=\"2022-08-16T13:20:00Z\">08\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-12T04:00:00Z\">08\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022\">Rev Products LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Rev Products LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1309 Coffeen Avenue, Suite 2579\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sheridan\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@revecig.com\"> info@revecig.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tobacco Products Manufactured in an Unregistered Establishment Are Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&amp;C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\u003C\u002Fp>\n\n\u003Cp>Because your establishment was not registered in accordance with section 905(c) of the FD&amp;C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Cloud Peak Law, LLC\u003Cbr>\nAttn: Andrew Pierce\u003Cbr>\n1095 Sugar View Dr., Ste. 500\u003Cbr>\nSheridan, WY 828801\u003Cbr>\nreports@cloudpeaklaw.com\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nabuse@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>InMotion Hosting, Inc.\u003Cbr>\nabuse@inmotionhosting.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRev Products LLC\n\n1309 Coffeen Avenue, Suite 2579\n\nSheridan, WY 82801\n\nUnited States\n\ninfo@revecig.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 12, 2022\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nTobacco Products Manufactured in an Unregistered Establishment Are Misbranded\n\nOur review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\n\nBecause your establishment was not registered in accordance with section 905(c) of the FD&C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nCloud Peak Law, LLC\n\nAttn: Andrew Pierce\n\n1095 Sugar View Dr., Ste. 500\n\nSheridan, WY 828801\n\nreports@cloudpeaklaw.com\n\nDomains By Proxy, LLC\n\nabuse@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nInMotion Hosting, Inc.\n\nabuse@inmotionhosting.com","Rev Products LLC","rev-products-llc-639730-08122022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022","2026-10-26T08:09:49.092354+00:00","2022-08-16","639730","2026-08-20T01:40:04.669+00:00","2022-08-12",{"id":154,"raw":155,"subject":160,"body_html":161,"body_text":162,"firm_name":163,"letter_id":164,"created_at":146,"fei_number":19,"letter_url":165,"updated_at":166,"action_type":22,"case_status":23,"posted_date":167,"marcs_cms_no":168,"product_type":169,"closeout_date":19,"issuing_office":159,"recipient_name":170,"body_fetched_at":171,"delivery_method":172,"recipient_title":19,"reference_number":19,"action_taken_date":173,"medical_device_id":19,"response_letter_date":19},2586,[156,157,158,159,160,13,13,13],"\u003Ctime datetime=\"2022-07-12T12:30:00Z\">07\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-01T04:00:00Z\">07\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F1am-usa-incorporated-dba-pleasure-products-usa-627006-07012022\">1am USA Incorporated dba Pleasure Products USA\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Internet Marketing of Unapproved and Misbranded Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brent Lawson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>1am USA Incorporated dba Pleasure Products USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6603 Crimson Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Barnhart\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63012\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@pleasureproductsusa.com\"> sales@pleasureproductsusa.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:IAMDOLLUSA@yahoo.com\"> IAMDOLLUSA@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 627006\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Lawson,\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) obtained samples of your product X RATED HONEY FOR MEN, purchased directly from your website www.pleasureproductsusa.com. FDA also reviewed your website in June 2022. Based on our review of your website and laboratory analysis of your product, FDA has identified serious violations of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Prohibited Act under Section 301(ll)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA confirmed through laboratory analysis that samples of your X RATED HONEY FOR MEN contains the undeclared active pharmaceutical ingredient tadalafil, which is a phosphodiesterase type-5 (PDE-5) inhibitor. Tadalafil is the active ingredient in the FDA-approved prescription drug Cialis, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.\u003C\u002Fp>\n\n\u003Cp>Subject to a limited exception, it is a prohibited act under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)] to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&amp;C Act [21 U.S.C. 355] or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to tadalafil.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FDA is not aware of any evidence that would call into question its conclusion that section 301(ll) of the FD&amp;C Act prohibits the introduction into interstate commerce of any food to which tadalafil has been added.\u003C\u002Fp>\n\n\u003Cp>Your X RATED HONEY FOR MEN product is a food to which tadalafil has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement Labeling\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You market X RATED HONEY FOR MEN as a dietary supplement. For example, the product webpage describes the product as a supplement and displays a product label image with “Supplement Facts.” However, this product cannot be dietary supplement because it does not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act [21 U.S.C. 321(ff)]. FDA has concluded, based on available evidence, that tadalafil products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, [21 U.S.C. 321(ff)(3)(B)(i) and (ii)]. Under those provisions, if an article (such as tadalafil) is an active ingredient in a drug product that has been approved under section 505 of the FD&amp;C Act, [21 U.S.C. 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for tadalafil. FDA is not aware of any evidence that would call into question its current conclusion that tadalafil products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, but you may present FDA with any evidence that has bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Additionally, we have the following comment:\u003C\u002Fp>\n\n\u003Cp>FDA has not conducted a complete review of your inventory. It is your responsibility under the Act to ensure that products marketed by your firm do not contain undeclared ingredients and comply with all requirements of federal law and regulations. A full list of all tainted products discovered by FDA can be found at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder\u003C\u002Fa>. We recommend that you subscribe to our email service at&nbsp;\u003Ca href=\"https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew\">https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew\u003C\u002Fa> to receive regular notices about tainted products discovered by FDA.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply to the above violations should be directed to Jamie Bumpas with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA approved Cialis™ (containing tadalafil as the active ingredient) as a new drug on November 21, 2003. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on available evidence, FDA has concluded that this is not the case for tadalafil.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nBrent Lawson\n\n1am USA Incorporated dba Pleasure Products USA\n\n6603 Crimson Lane\n\nBarnhart, MO 63012\n\nUnited States\n\nsales@pleasureproductsusa.com\n\nIAMDOLLUSA@yahoo.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nJuly 1, 2022\n\nRE: 627006\n\nDear Mr. Lawson,\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) obtained samples of your product X RATED HONEY FOR MEN, purchased directly from your website www.pleasureproductsusa.com. FDA also reviewed your website in June 2022. Based on our review of your website and laboratory analysis of your product, FDA has identified serious violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act).\n\nProhibited Act under Section 301(ll)\n\nFDA confirmed through laboratory analysis that samples of your X RATED HONEY FOR MEN contains the undeclared active pharmaceutical ingredient tadalafil, which is a phosphodiesterase type-5 (PDE-5) inhibitor. Tadalafil is the active ingredient in the FDA-approved prescription drug Cialis, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.\n\nSubject to a limited exception, it is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)] to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&C Act [21 U.S.C. 355] or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to tadalafil.1 FDA is not aware of any evidence that would call into question its conclusion that section 301(ll) of the FD&C Act prohibits the introduction into interstate commerce of any food to which tadalafil has been added.\n\nYour X RATED HONEY FOR MEN product is a food to which tadalafil has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&C Act.\n\nDietary Supplement Labeling\n\nYou market X RATED HONEY FOR MEN as a dietary supplement. For example, the product webpage describes the product as a supplement and displays a product label image with “Supplement Facts.” However, this product cannot be dietary supplement because it does not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act [21 U.S.C. 321(ff)]. FDA has concluded, based on available evidence, that tadalafil products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, [21 U.S.C. 321(ff)(3)(B)(i) and (ii)]. Under those provisions, if an article (such as tadalafil) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act, [21 U.S.C. 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for tadalafil. FDA is not aware of any evidence that would call into question its current conclusion that tadalafil products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nAdditionally, we have the following comment:\n\nFDA has not conducted a complete review of your inventory. It is your responsibility under the Act to ensure that products marketed by your firm do not contain undeclared ingredients and comply with all requirements of federal law and regulations. A full list of all tainted products discovered by FDA can be found at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder. We recommend that you subscribe to our email service at https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew to receive regular notices about tainted products discovered by FDA.\n\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply to the above violations should be directed to Jamie Bumpas with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n____________________________\n\n1 FDA approved Cialis™ (containing tadalafil as the active ingredient) as a new drug on November 21, 2003. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on available evidence, FDA has concluded that this is not the case for tadalafil.","1am USA Incorporated dba Pleasure Products USA","1am-usa-incorporated-dba-pleasure-products-usa-627006-07012022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F1am-usa-incorporated-dba-pleasure-products-usa-627006-07012022","2026-10-26T08:07:47.335951+00:00","2022-07-12","627006","DrugsFood & Beverages","Brent Lawson","2026-08-20T01:46:20.803+00:00","Via Overnight Delivery","2022-07-01",{"id":175,"raw":176,"subject":181,"body_html":182,"body_text":183,"firm_name":184,"letter_id":185,"created_at":186,"fei_number":19,"letter_url":187,"updated_at":188,"action_type":22,"case_status":23,"posted_date":189,"marcs_cms_no":190,"product_type":191,"closeout_date":19,"issuing_office":192,"recipient_name":193,"body_fetched_at":194,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":195,"medical_device_id":19,"response_letter_date":19},2140,[177,178,179,180,181,13,13,13],"\u003Ctime datetime=\"2023-04-04T13:20:00Z\">04\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-23T04:00:00Z\">03\u002F23\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynovo-production-inc-647427-03232023\">Synovo Production, Inc.\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations West","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Woojoo Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Synovo Production, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1501 N Harbor Blvd Ste 209\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fullerton\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92835-3803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ceo@synovopro.com\"> ceo@synovopro.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER CMS # 647427\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 23, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kim:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Synovo Production, Inc. (Synovo or “the firm”), located in Fullerton, CA, on October 11, 2022, through October 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer, manufacturer, and distributor of the “Femoral Resurfacing Cup,” which is distributed both as a stand-alone product and marketed as a component of the “Total Hip System.”\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Both these products are intended for a range of orthopedic procedures, including, but not limited to, hip arthroplasty and reconstruction. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man, or intended to affect the structure or any function of the body of man.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm currently holds a 510(k) clearance for the Femoral Resurfacing Cup. This device was cleared on May 23, 1991 under K904870 with the name “Modified New Jersey Femoral Hip Resurfacing Component” and was assigned product code KXA. This device was cleared, among other things, for painful hip cup arthroplasty. The clearance letter associated with this device further advised that:\u003C\u002Fp>\n\n\u003Cp>1. This device may not be labeled or promoted for non-cemented use.\u003C\u002Fp>\n\n\u003Cp>2. All labeling for this device, including package label and labeling included within the package, must prominently state that the device is intended for cemented use only.\u003C\u002Fp>\n\n\u003Cp>3. Any non-cemented fixation of this device is considered investigational and may only be investigated as a significant risk device in accordance with the investigational device exemption regulation under 21 CFR, Part 812. All users of the device for non-cemented fixation must receive approval from their respective institutional review boards and the Food and Drug Administration to conduct the investigation.\u003C\u002Fp>\n\n\u003Cp>However, since the time it was cleared, the Femoral Resurfacing Cup has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, significant changes to the Femoral Resurfacing Cup’s fixation have been made that include, among other things, a change to the coating specifications and associated differences in intended use. According to the instructions for use collected during the inspection, “the underside of the resurfacing component has a coating for \u003Cem>cementless fixation\u003C\u002Fem>” (emphasis added), which is contradictory to the K904870 clearance letter. The referenced changes, individually and collectively, are likely to expose patients to increased risks of loosening and subsequent revision surgery (e.g., from pain, proximal femur fracture, or component fracture).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> These and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the further modified Femoral Resurfacing Cup (See 21 CFR 807.81(a)(3)).\u003C\u002Fp>\n\n\u003Cp>You did not submit any new 510(k) for the referenced modifications to the Femoral Resurfacing Cup. The Femoral Resurfacing Cup, when distributed as an individual device separate from the Total Hip System, is therefore misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of this device, as required by section 510(k) of the Act.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the Femoral Resurfacing Cup is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that you are also marketing the Femoral Resurfacing Cup as a component of the Total Hip System. Specifically, based on the totality of the labeling collected during inspection, the Total Hip System is intended for use as a semi-constrained total hip joint replacement device composed of an acetabular fixation cup with a polyethylene bearing surface in combination with a femoral resurfacing cup. FDA has classified this type of hip joint replacement device as class III under 21 CFR 888.3410 (product codes KXB for cemented prostheses or OCG for non-cemented prostheses). These class III device types require submission and approval of a PMA in order to obtain marketing authorization.\u003C\u002Fp>\n\n\u003Cp>The Total Hip System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved PMA in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Total Hip System is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the Total Hip System device and Femoral Resurfacing Cup are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to validate according to established procedures where results of a process cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, you changed the biologic fixation coating for the hip replacement system from a sintered beads porous coating to a Titanium Plasma Spray (TPS) coating in April 2020. You have a Letter to File for the process change, but you could not provide evidence that a validation was performed for the change. You also discontinued the second machining process for the Femoral Resurfacing Component, but you could not provide evidence that a validation was performed for the process change. You did not follow your Process Control SOP2-007, Rev. D which states that re-validation shall be considered, and typically required, for a manufacturing process change.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically, per a request from a surgeon in July 2022, you manufactured three units of a Femoral Resurfacing Cup Lot 01030049T to shorten the stem by 1cm. You did not follow your Design Control SOP-008, Rev. D in that you did not manage the change by documenting the design change, perform appropriate verification and validation, and keep a record of reviews.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a). Specifically, your firm opened Process CAR 1008 to address the issue of the TPS coating adhering poorly to the Femoral Resurfacing Component. You determined that a second machining process was causing delamination of the coating and you removed the second machining process. You received sample parts from DOT America and certificates from the supplier SynusBio for the new lot, but you could not provide evidence that the corrective action was found to be effective. You did not follow your Corrective Action and Preventive Action SOP2-014, Rev. D which states that effectivity checks should be performed at an appropriate time after the corrective action file has been closed.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. Specifically, your firm was unable to provide a supplier assessment form for your re-packager\u002Fsterilizer BioPro, Inc. You did not follow your Supplier Qualification SOP2-028, Rev. C which states that a Supplier\u002FConsultant Form (SOP2-028-01) will be completed to document preliminary information about the supplier; that QA\u002FRA will review the information as to whether to proceed with the qualification process; and that qualification occurs before utilizing the supplier\u002Fconsultant. During the inspection, you also completed an initial supplier assessment for your supplier of raw materials, SynusBio, but had not completed it prior to utilizing the supplier.\u003C\u002Fp>\n\n\u003Cp>5. Failure to document the dates and results of quality system reviews by management with executive responsibility as required by 21 CFR 820.20(c). Specifically, your firm could not provide evidence that it conducted management reviews since its inception in April 2020. You did not follow your Management Review SOP2-011, Rev. D which states that at least once a year top management will meet to review the suitability and effectiveness of the quality system.\u003C\u002Fp>\n\n\u003Cp>6. Failure to conduct quality audits as required by 21 CFR 820.22. Specifically, your firm could not provide evidence that an annual audit had occurred in 2021. You did not follow your Internal Audit SOP2-024, Rev. D which states that each quality system element listed on the audit schedule will be audited at a minimum of once per year.\u003C\u002Fp>\n\n\u003Cp>7. Failure to document personnel training as required by 820.25(b). Specifically, your firm could not provide training records for your Regulatory Affairs (RA) Manager. You did not follow your Training and Personnel Qualification SOP2-018, Rev. D which states that a training record form (SOP-018-91) and electronic documentation of training shall be completed. The RA Manager also stated that your firm does not have training records for your firm’s other employees.\u003C\u002Fp>\n\n\u003Cp>Furthermore, under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means (section 510(p) of the Act, 21 U.S.C. § 360(p)), during the period beginning October 1st and ending December 31st of each year. Our inspection revealed that your firm was not currently registered with FDA as a device specification developer, manufacturer, or distributor, nor were any of the devices associated with your firm listed with FDA. You indicated to our inspector that you would complete the registration and listing process. As of the date of this letter, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2023.\u003C\u002Fp>\n\n\u003Cp>Therefore, all your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\n\n\u003Cp>During our inspection of your firm, you indicated that Synovo would respond in writing within fifteen business days after the completion of the inspection. As of the date of this letter, FDA has not received such response.\u003C\u002Fp>\n\n\u003Cp>Your firm should immediately cease manufacture of the Total Hip System and Femoral Resurfacing Cup with the modified underside and labeled for non-cemented use and take prompt action to correct the violations addressed in this letter. Failure to address this matter promptly and adequately may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov. Refer to CMS # 647427 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Raquel Peat, PhD, MPH, USPHS\u003Cbr>\nDirector\u003Cbr>\nOHT 6: Office of Orthopedic Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The Total Hip System is also referred to in labeling for the Femoral Resurfacing Cup as the “Synovo Hip Replacement System.” The Total Hip System is also comprised of additional components, including but not limited to the “Acetabular Fixation Cup” and “Acetabular Bearing.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Additionally, you have changed the coating specifications of the “Acetabular Fixation Cup” cleared under K963101 which also exposes patients to increased risks of loosening and subsequent revision surgery.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Woojoo Kim\n\nRecipient Title\n\nCEO\n\nSynovo Production, Inc.\n\n1501 N Harbor Blvd Ste 209\n\nFullerton, CA 92835-3803\n\nUnited States\n\nceo@synovopro.com\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER CMS # 647427\n\nMarch 23, 2023\n\nDear Mr. Kim:\n\nDuring an inspection of your firm, Synovo Production, Inc. (Synovo or “the firm”), located in Fullerton, CA, on October 11, 2022, through October 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer, manufacturer, and distributor of the “Femoral Resurfacing Cup,” which is distributed both as a stand-alone product and marketed as a component of the “Total Hip System.”1 Both these products are intended for a range of orthopedic procedures, including, but not limited to, hip arthroplasty and reconstruction. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man, or intended to affect the structure or any function of the body of man.\n\nOur inspection revealed that your firm currently holds a 510(k) clearance for the Femoral Resurfacing Cup. This device was cleared on May 23, 1991 under K904870 with the name “Modified New Jersey Femoral Hip Resurfacing Component” and was assigned product code KXA. This device was cleared, among other things, for painful hip cup arthroplasty. The clearance letter associated with this device further advised that:\n\n1. This device may not be labeled or promoted for non-cemented use.\n\n2. All labeling for this device, including package label and labeling included within the package, must prominently state that the device is intended for cemented use only.\n\n3. Any non-cemented fixation of this device is considered investigational and may only be investigated as a significant risk device in accordance with the investigational device exemption regulation under 21 CFR, Part 812. All users of the device for non-cemented fixation must receive approval from their respective institutional review boards and the Food and Drug Administration to conduct the investigation.\n\nHowever, since the time it was cleared, the Femoral Resurfacing Cup has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, significant changes to the Femoral Resurfacing Cup’s fixation have been made that include, among other things, a change to the coating specifications and associated differences in intended use. According to the instructions for use collected during the inspection, “the underside of the resurfacing component has a coating for cementless fixation” (emphasis added), which is contradictory to the K904870 clearance letter. The referenced changes, individually and collectively, are likely to expose patients to increased risks of loosening and subsequent revision surgery (e.g., from pain, proximal femur fracture, or component fracture).2 These and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the further modified Femoral Resurfacing Cup (See 21 CFR 807.81(a)(3)).\n\nYou did not submit any new 510(k) for the referenced modifications to the Femoral Resurfacing Cup. The Femoral Resurfacing Cup, when distributed as an individual device separate from the Total Hip System, is therefore misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of this device, as required by section 510(k) of the Act.\n\nOur inspection also revealed that the Femoral Resurfacing Cup is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nOur inspection revealed that you are also marketing the Femoral Resurfacing Cup as a component of the Total Hip System. Specifically, based on the totality of the labeling collected during inspection, the Total Hip System is intended for use as a semi-constrained total hip joint replacement device composed of an acetabular fixation cup with a polyethylene bearing surface in combination with a femoral resurfacing cup. FDA has classified this type of hip joint replacement device as class III under 21 CFR 888.3410 (product codes KXB for cemented prostheses or OCG for non-cemented prostheses). These class III device types require submission and approval of a PMA in order to obtain marketing authorization.\n\nThe Total Hip System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved PMA in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Total Hip System is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that the Total Hip System device and Femoral Resurfacing Cup are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to validate according to established procedures where results of a process cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, you changed the biologic fixation coating for the hip replacement system from a sintered beads porous coating to a Titanium Plasma Spray (TPS) coating in April 2020. You have a Letter to File for the process change, but you could not provide evidence that a validation was performed for the change. You also discontinued the second machining process for the Femoral Resurfacing Component, but you could not provide evidence that a validation was performed for the process change. You did not follow your Process Control SOP2-007, Rev. D which states that re-validation shall be considered, and typically required, for a manufacturing process change.\n\n2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically, per a request from a surgeon in July 2022, you manufactured three units of a Femoral Resurfacing Cup Lot 01030049T to shorten the stem by 1cm. You did not follow your Design Control SOP-008, Rev. D in that you did not manage the change by documenting the design change, perform appropriate verification and validation, and keep a record of reviews.\n\n3. Failure to establish procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a). Specifically, your firm opened Process CAR 1008 to address the issue of the TPS coating adhering poorly to the Femoral Resurfacing Component. You determined that a second machining process was causing delamination of the coating and you removed the second machining process. You received sample parts from DOT America and certificates from the supplier SynusBio for the new lot, but you could not provide evidence that the corrective action was found to be effective. You did not follow your Corrective Action and Preventive Action SOP2-014, Rev. D which states that effectivity checks should be performed at an appropriate time after the corrective action file has been closed.\n\n4. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. Specifically, your firm was unable to provide a supplier assessment form for your re-packager\u002Fsterilizer BioPro, Inc. You did not follow your Supplier Qualification SOP2-028, Rev. C which states that a Supplier\u002FConsultant Form (SOP2-028-01) will be completed to document preliminary information about the supplier; that QA\u002FRA will review the information as to whether to proceed with the qualification process; and that qualification occurs before utilizing the supplier\u002Fconsultant. During the inspection, you also completed an initial supplier assessment for your supplier of raw materials, SynusBio, but had not completed it prior to utilizing the supplier.\n\n5. Failure to document the dates and results of quality system reviews by management with executive responsibility as required by 21 CFR 820.20(c). Specifically, your firm could not provide evidence that it conducted management reviews since its inception in April 2020. You did not follow your Management Review SOP2-011, Rev. D which states that at least once a year top management will meet to review the suitability and effectiveness of the quality system.\n\n6. Failure to conduct quality audits as required by 21 CFR 820.22. Specifically, your firm could not provide evidence that an annual audit had occurred in 2021. You did not follow your Internal Audit SOP2-024, Rev. D which states that each quality system element listed on the audit schedule will be audited at a minimum of once per year.\n\n7. Failure to document personnel training as required by 820.25(b). Specifically, your firm could not provide training records for your Regulatory Affairs (RA) Manager. You did not follow your Training and Personnel Qualification SOP2-018, Rev. D which states that a training record form (SOP-018-91) and electronic documentation of training shall be completed. The RA Manager also stated that your firm does not have training records for your firm’s other employees.\n\nFurthermore, under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means (section 510(p) of the Act, 21 U.S.C. § 360(p)), during the period beginning October 1st and ending December 31st of each year. Our inspection revealed that your firm was not currently registered with FDA as a device specification developer, manufacturer, or distributor, nor were any of the devices associated with your firm listed with FDA. You indicated to our inspector that you would complete the registration and listing process. As of the date of this letter, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2023.\n\nTherefore, all your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\n\nDuring our inspection of your firm, you indicated that Synovo would respond in writing within fifteen business days after the completion of the inspection. As of the date of this letter, FDA has not received such response.\n\nYour firm should immediately cease manufacture of the Total Hip System and Femoral Resurfacing Cup with the modified underside and labeled for non-cemented use and take prompt action to correct the violations addressed in this letter. Failure to address this matter promptly and adequately may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov. Refer to CMS # 647427 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Raquel Peat, PhD, MPH, USPHS\n\nDirector\n\nOHT 6: Office of Orthopedic Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest\n\n____________________________\n\n1 The Total Hip System is also referred to in labeling for the Femoral Resurfacing Cup as the “Synovo Hip Replacement System.” The Total Hip System is also comprised of additional components, including but not limited to the “Acetabular Fixation Cup” and “Acetabular Bearing.”\n\n2 Additionally, you have changed the coating specifications of the “Acetabular Fixation Cup” cleared under K963101 which also exposes patients to increased risks of loosening and subsequent revision surgery.","Synovo Production, Inc.","synovo-production-inc-647427-03232023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynovo-production-inc-647427-03232023","2026-10-26T08:10:09.218108+00:00","2023-04-04","647427","Medical Devices","Division of Medical Device and Radiological Health Operations West","Mr. Woojoo Kim","2026-08-20T01:10:23.537+00:00","2023-03-23",{"id":197,"raw":198,"subject":203,"body_html":204,"body_text":205,"firm_name":206,"letter_id":207,"created_at":146,"fei_number":19,"letter_url":208,"updated_at":209,"action_type":22,"case_status":23,"posted_date":210,"marcs_cms_no":211,"product_type":212,"closeout_date":19,"issuing_office":202,"recipient_name":213,"body_fetched_at":214,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":215,"medical_device_id":19,"response_letter_date":19},2734,[199,200,201,202,203,13,13,13],"\u003Ctime datetime=\"2022-04-19T13:20:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-13T04:00:00Z\">04\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fultimark-products-628389-04132022\">Ultimark Products\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Zuckerberg\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Ultimark Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2250 Hickory Road, Suite 150\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Plymouth Meeting\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19462\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Daz91146@aol.com\"> Daz91146@aol.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 13, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Zuckerberg,\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. PORCELANA DAY SKIN LIGHTENING CREAM drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>PORCELANA DAY SKIN LIGHTENING CREAM is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product label and labeling from your website Porcelana.com, where the product is available for purchase, that provide evidence of the intended use (as defined in 21 CFR 201.128) of your product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“SKIN LIGHTENING CREAM . . . FADES DARK SPOTS . . . Skin lightener . . . Porcelana® Day fades away dull, uneven skin tones . . . fades discolorations, blemishes and dark spots . . . \u003Cstrong>Drug facts\u003C\u002Fstrong> . . . \u003Cstrong>Active Ingredients\u003C\u002Fstrong> . . . Hydroquinone U.S.P. 2% . . . Skin Lightener . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For the gradual fading of dark spots in the skin such as liver and age spots.” [from your product label PORCELANA DAY SKIN LIGHTENING CREAM]\u003C\u002Fp>\n\n\u003Cp>“The Porcelana Day Cream includes active skin lighteners to create and maintain a luminous even skin tone. Its lightening properties are never compromised because the Porcelana Day Cream also comes infused with sunscreen and antioxidants.” [from your website https:\u002F\u002Fwww.shopcca.com\u002Fcollections\u002Fporcelana]\u003C\u002Fp>\n\n\u003Cp>PORCELANA DAY SKIN LIGHTENING CREAM is a skin bleaching drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this skin bleaching product falls under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because it is subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, PORCELANA DAY SKIN LIGHTENING CREAM is deemed to be a new drug under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for PORCELANA DAY SKIN LIGHTENING CREAM. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Moreover, PORCELANA DAY SKIN LIGHTENING CREAM is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is deemed as such under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor is the skin bleaching\u002Fskin lightening drug product named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003Cbr>\n\u003Cbr>\nFailure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355Gh(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDavid Zuckerberg\n\nUltimark Products\n\n2250 Hickory Road, Suite 150\n\nPlymouth Meeting, PA 19462\n\nUnited States\n\nDaz91146@aol.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: April 13, 2022\n\nDear Mr. Zuckerberg,\n\nThis letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. PORCELANA DAY SKIN LIGHTENING CREAM drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nPORCELANA DAY SKIN LIGHTENING CREAM is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\n\nExamples of the claims observed on your product label and labeling from your website Porcelana.com, where the product is available for purchase, that provide evidence of the intended use (as defined in 21 CFR 201.128) of your product include, but may not be limited to, the following:\n\n“SKIN LIGHTENING CREAM . . . FADES DARK SPOTS . . . Skin lightener . . . Porcelana® Day fades away dull, uneven skin tones . . . fades discolorations, blemishes and dark spots . . . Drug facts . . . Active Ingredients . . . Hydroquinone U.S.P. 2% . . . Skin Lightener . . . Uses . . . For the gradual fading of dark spots in the skin such as liver and age spots.” [from your product label PORCELANA DAY SKIN LIGHTENING CREAM]\n\n“The Porcelana Day Cream includes active skin lighteners to create and maintain a luminous even skin tone. Its lightening properties are never compromised because the Porcelana Day Cream also comes infused with sunscreen and antioxidants.” [from your website https:\u002F\u002Fwww.shopcca.com\u002Fcollections\u002Fporcelana]\n\nPORCELANA DAY SKIN LIGHTENING CREAM is a skin bleaching drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this skin bleaching product falls under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because it is subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, PORCELANA DAY SKIN LIGHTENING CREAM is deemed to be a new drug under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for PORCELANA DAY SKIN LIGHTENING CREAM. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\n\nIntroduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMoreover, PORCELANA DAY SKIN LIGHTENING CREAM is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is deemed as such under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor is the skin bleaching\u002Fskin lightening drug product named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nCC:\n\n(b)(4)\n\n____________________________\n\n1 On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\n\n2 Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355Gh(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.","Ultimark Products","ultimark-products-628389-04132022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fultimark-products-628389-04132022","2026-10-26T08:10:16.833712+00:00","2022-04-19","628389","Drugs","David Zuckerberg","2026-08-20T02:00:30.087+00:00","2022-04-13",{"id":217,"raw":218,"subject":222,"body_html":223,"body_text":224,"firm_name":225,"letter_id":226,"created_at":146,"fei_number":19,"letter_url":227,"updated_at":228,"action_type":22,"case_status":23,"posted_date":229,"marcs_cms_no":230,"product_type":212,"closeout_date":19,"issuing_office":202,"recipient_name":231,"body_fetched_at":232,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":233,"medical_device_id":19,"response_letter_date":19},2794,[219,220,221,202,222,13,13,13],"\u003Ctime datetime=\"2022-03-28T14:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-25T04:00:00Z\">03\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiodine-products-inc-628296-03252022\">Iodine Products Inc\u003C\u002Fa>","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gene Rosov\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Iodine Products Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8025 SW 63rd Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>So. Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33143\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:erosov@iodineproducts.com\"> erosov@iodineproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: CMS# 628296\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 25, 2022\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.iodineproducts.com on March 2, 2022, and March 23, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos, https:\u002F\u002Fwww.facebook.com\u002FIodineProducts, and https:\u002F\u002Fwww.instagram.com\u002Fiodineproducts\u002F?hl=en, where you direct consumers to your website, http:\u002F\u002Fwww.iodineproducts.com\u002F, to purchase your products. The FDA has observed that your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Our new Anti-Viral Liquid Mask is a COVID KILLER. Once you use it, you’re protected. Doctors use it to prevent the transmission of COVID-19 between doctors, staff and patients worldwide. It works! . . . In your mouth. Spray 2-3 times in your mouth. Breathe inwards to pull the iodine aerosol into your throat . . . In your nose . . . make sure to get 1-2 sprays directly into your nose. Sniff to pull it upward.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-sprayanti-viral-large\u002F]\u003C\u002Fli>\n\t\u003Cli>“Lab and clinical studies show it kills ALL viruses, including the COVID-19 coronavirus, on contact in 15-30 seconds . . . A recent clinical study proves that the active ingredients in our 10 ml Liquid Mask CURE COVID-19 patients and simultaneously PREVENT transmission as they kill COVID-19 virus particles . . . Tags: anti-viral, COVID, COVID-19, Cure” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-spray-anti-viral-large\u002F]\u003C\u002Fli>\n\t\u003Cli>“The COVID-Killer 10 Ml Liquid Mask Anti-Viral Spray . . . Our 10-day 10 ml Liquid Mask is a COVID-19 virus killer. It sprays easily into nose and throat where it forms a protective coating that will last. Moreover, if you do come in to contact with a virus, such as . . . COVID . . . the iodine in the mask spray will kill is [sic] on contact within seconds . . . There are more studies that show that iodine kills COVID-19.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002F10-ml-liquidmask-anti-viral-nose-throat-spray-small\u002F]\u003C\u002Fli>\n\t\u003Cli>“Liquid Mask – only at iodineproducts.com – to Prevent COVID transmission . . . To truly prevent the transmission of this disease organism (the SARS-CoV-2 virus), you need Liquid Mask.” [from a January 8, 2021 post on your YouTube webpage https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos]\u003C\u002Fli>\n\t\u003Cli>“Our new free LIQUID MASK is a viral killer . . . This product in various forms is being used . . . to prevent the transmission of COVID-19 . . . PREVENT COVID! . . . Use our FREE Covid Killing Liquid Mask . . .” [from a January 11, 2021 post on your Facebook webpage https:\u002F\u002Fwww.facebook.com\u002FIodineProducts]\u003C\u002Fli>\n\t\u003Cli>“#11 of 19 Ways to Avoid Covid-19 . . . Tip #11 Get Liquid Mask . . . Liquid Mask kills the virus . . . #covid #covid_19 . . . #tipsforcovid19 #Covidtips #Covidfree . . . #covidrelief #covidliquidmasks” [from a February 28, 2021 post on your Instagram webpage https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCL1eUlCHIeM\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley&nbsp;\u003Cbr>\nDirector&nbsp;\u003Cbr>\nOffice of Compliance&nbsp;\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>_____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGene Rosov\n\nIodine Products Inc\n\n8025 SW 63rd Place\n\nSo. Miami, FL 33143\n\nUnited States\n\nerosov@iodineproducts.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRE: CMS# 628296\n\nDate: March 25, 2022\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.iodineproducts.com on March 2, 2022, and March 23, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos, https:\u002F\u002Fwww.facebook.com\u002FIodineProducts, and https:\u002F\u002Fwww.instagram.com\u002Fiodineproducts\u002F?hl=en, where you direct consumers to your website, http:\u002F\u002Fwww.iodineproducts.com\u002F, to purchase your products. The FDA has observed that your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Our new Anti-Viral Liquid Mask is a COVID KILLER. Once you use it, you’re protected. Doctors use it to prevent the transmission of COVID-19 between doctors, staff and patients worldwide. It works! . . . In your mouth. Spray 2-3 times in your mouth. Breathe inwards to pull the iodine aerosol into your throat . . . In your nose . . . make sure to get 1-2 sprays directly into your nose. Sniff to pull it upward.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-sprayanti-viral-large\u002F]\n\n“Lab and clinical studies show it kills ALL viruses, including the COVID-19 coronavirus, on contact in 15-30 seconds . . . A recent clinical study proves that the active ingredients in our 10 ml Liquid Mask CURE COVID-19 patients and simultaneously PREVENT transmission as they kill COVID-19 virus particles . . . Tags: anti-viral, COVID, COVID-19, Cure” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-spray-anti-viral-large\u002F]\n\n“The COVID-Killer 10 Ml Liquid Mask Anti-Viral Spray . . . Our 10-day 10 ml Liquid Mask is a COVID-19 virus killer. It sprays easily into nose and throat where it forms a protective coating that will last. Moreover, if you do come in to contact with a virus, such as . . . COVID . . . the iodine in the mask spray will kill is [sic] on contact within seconds . . . There are more studies that show that iodine kills COVID-19.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002F10-ml-liquidmask-anti-viral-nose-throat-spray-small\u002F]\n\n“Liquid Mask – only at iodineproducts.com – to Prevent COVID transmission . . . To truly prevent the transmission of this disease organism (the SARS-CoV-2 virus), you need Liquid Mask.” [from a January 8, 2021 post on your YouTube webpage https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos]\n\n“Our new free LIQUID MASK is a viral killer . . . This product in various forms is being used . . . to prevent the transmission of COVID-19 . . . PREVENT COVID! . . . Use our FREE Covid Killing Liquid Mask . . .” [from a January 11, 2021 post on your Facebook webpage https:\u002F\u002Fwww.facebook.com\u002FIodineProducts]\n\n“#11 of 19 Ways to Avoid Covid-19 . . . Tip #11 Get Liquid Mask . . . Liquid Mask kills the virus . . . #covid #covid_19 . . . #tipsforcovid19 #Covidtips #Covidfree . . . #covidrelief #covidliquidmasks” [from a February 28, 2021 post on your Instagram webpage https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCL1eUlCHIeM\u002F]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n_____________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Iodine Products Inc","iodine-products-inc-628296-03252022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiodine-products-inc-628296-03252022","2026-10-26T08:09:00.755596+00:00","2022-03-28","628296","Gene Rosov","2026-08-20T02:04:46.116+00:00","2022-03-25",{"id":235,"raw":236,"subject":37,"body_html":240,"body_text":241,"firm_name":242,"letter_id":243,"created_at":186,"fei_number":19,"letter_url":244,"updated_at":245,"action_type":22,"case_status":23,"posted_date":246,"marcs_cms_no":247,"product_type":46,"closeout_date":19,"issuing_office":36,"recipient_name":248,"body_fetched_at":249,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":250,"medical_device_id":19,"response_letter_date":19},2424,[237,238,239,36,37,13,13,13],"\u003Ctime datetime=\"2022-09-27T13:20:00Z\">09\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-02T04:00:00Z\">09\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fel-salvador-products-inc-640532-09022022\">El Salvador Products Inc\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Santos David Velasquez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>El Salvador Products Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>12130 Dairy Ashford\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sugarland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77478\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 02, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS# 640532\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Santos David Velasquez:\u003C\u002Fp>\n\n\u003Cp>On June 3 - 8, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of El Salvador Products Inc. located at 12130 Dairy Ashford Sugarland, TX 77478. We also conducted an inspection on May 21 - 23, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We have not received your response to the Form FDA 483a issued on June 8, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any foods that you import, including the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Salsa &amp; Queso Chips and Sweet Bread imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Pineapple Pastry imported from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your facility at 12130 Dairy Ashford Sugarland, TX 77478 is subject to the registration requirement in section 415 of the FD&amp;C Act (21 U.S.C. § 350 d) and our implementing regulations at 21 CFR Part 1, Subpart H. Section 415(a)(3) of the FD&amp;C Act requires facilities that are required to register with FDA to renew their registrations during the period beginning on October 1 and ending on December 31 of each even-numbered year. During the inspection you were advised of these requirements. Our records indicate that as of the date of this letter, your firm does not have a valid food facility registration. The failure to register a facility as required is a prohibited act under section 301(dd) of the FD&amp;C Act (21 U.S.C. § 331(dd)).\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Juan Daniel Garza III, Compliance Officer, US FDA, 216 W. Village Blvd., Suite 107, Laredo, TX 78041. If you have any questions regarding this letter, you may contact CO Garza via email at juan.garza@fda.hhs.gov. Please reference CMS# 640532 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDivision Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Santos David Velasquez\n\nRecipient Title\n\nCEO\n\nEl Salvador Products Inc\n\n12130 Dairy Ashford\n\nSugarland, TX 77478\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nSeptember 02, 2022\n\nWARNING LETTER\n\nRe: CMS# 640532\n\nDear Mr. Santos David Velasquez:\n\nOn June 3 - 8, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of El Salvador Products Inc. located at 12130 Dairy Ashford Sugarland, TX 77478. We also conducted an inspection on May 21 - 23, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\n\nWe have not received your response to the Form FDA 483a issued on June 8, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any foods that you import, including the following foods:\n\nSalsa & Queso Chips and Sweet Bread imported from (b)(4), located in (b)(4)\n\nPineapple Pastry imported from foreign supplier (b)(4), located in (b)(4)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nAdditionally, we offer the following comment:\n\nFDA has determined that your facility at 12130 Dairy Ashford Sugarland, TX 77478 is subject to the registration requirement in section 415 of the FD&C Act (21 U.S.C. § 350 d) and our implementing regulations at 21 CFR Part 1, Subpart H. Section 415(a)(3) of the FD&C Act requires facilities that are required to register with FDA to renew their registrations during the period beginning on October 1 and ending on December 31 of each even-numbered year. During the inspection you were advised of these requirements. Our records indicate that as of the date of this letter, your firm does not have a valid food facility registration. The failure to register a facility as required is a prohibited act under section 301(dd) of the FD&C Act (21 U.S.C. § 331(dd)).\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\n(b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Juan Daniel Garza III, Compliance Officer, US FDA, 216 W. Village Blvd., Suite 107, Laredo, TX 78041. If you have any questions regarding this letter, you may contact CO Garza via email at juan.garza@fda.hhs.gov. Please reference CMS# 640532 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDivision Director\n\nDivision of Southwest Imports","El Salvador Products Inc","el-salvador-products-inc-640532-09022022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fel-salvador-products-inc-640532-09022022","2026-10-26T08:08:32.18636+00:00","2022-09-27","640532","Mr. Santos David Velasquez","2026-08-20T01:32:07.903+00:00","2022-09-02",{"id":252,"raw":253,"subject":257,"body_html":258,"body_text":259,"firm_name":260,"letter_id":261,"created_at":84,"fei_number":19,"letter_url":262,"updated_at":263,"action_type":22,"case_status":23,"posted_date":264,"marcs_cms_no":265,"product_type":212,"closeout_date":19,"issuing_office":100,"recipient_name":266,"body_fetched_at":267,"delivery_method":268,"recipient_title":19,"reference_number":269,"action_taken_date":270,"medical_device_id":19,"response_letter_date":19},365,[254,255,256,100,257,13,13,13],"\u003Ctime datetime=\"2026-01-20T05:00:00Z\">01\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-08T05:00:00Z\">01\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodrome-sciences-usa-llc-717959-01082026\">Prodrome Sciences USA, LLC\u003C\u002Fa>","Sponsor\u002FUnapproved Misbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-01-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dayan B. Goodenowe, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Prodrome Sciences USA, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>27518 Via Industria\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Temecula\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92590\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Goodenowe:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between December 17, 2024, and January 10, 2025. The investigator representing FDA reviewed the role of Prodrome Sciences USA, LLC (Prodrome Sciences) as the sponsor of a clinical investigation (Protocol Pro‐040‐Plasm‐01, “ProdromeNeuro: An Open-Label Study of Omega 3 Oil Nutritional Supplementation for Aging-Related Cognitive Decline”) of the investigational drug ProdromeNeuro™ Oil (Omega-3 Plasmalogens).\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your written responses to the Form FDA 483, dated January 23 and January 31, 2025.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated January 23 and January 31, 2025, it appears that Prodrome Sciences did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312) governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20 and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Prodrome Sciences failed to comply with these requirements. Specifically, Prodrome Sciences initiated and conducted Protocol Pro‐040‐Plasm‐01, a clinical investigation of the investigational drug ProdromeNeuro™ Oil, subject to section 505 of the FD&amp;C Act [21 U.S.C. 355], without submitting and having in effect an IND.\u003C\u002Fp>\u003Cp>In Prodrome Sciences’ January 31, 2025, written response to the Form FDA 483, you indicated that the objective of Protocol Pro‐040‐Plasm‐01 was to evaluate the safety and tolerability of ProdromeNeuro™ Oil as a nutritional supplement. Additionally, during the inspection you stated that the investigational product, ProdromeNeuro™ Oil, is a blend of naturally occurring alkylglycerols composed of docosahexaenoic acid (DHA) [22:6], docosapentaenoic acid (DPA) [22:5], and eicosapentaenoic acid (EPA) [20:5] fatty acids. You further stated that these dietary alkylglycerols are found naturally in shark liver oil, which makes ProdromeNeuro™ Oil a dietary supplement that does not require an IND.\u003C\u002Fp>\u003Cp>For the reasons described below, we conclude that the evidence collected during the inspection shows that ProdromeNeuro™ Oil was intended for use as a drug, not as a dietary supplement, for the clinical investigation conducted under Protocol Pro‐040‐Plasm‐01. Therefore, Prodrome Sciences was required to submit an IND before conducting the clinical investigation.\u003C\u002Fp>\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease….” Although Protocol Pro-040-Plasm-01 stated that the primary objective was to evaluate the safety and tolerability of ProdromeNeuro™ Oil in subjects with age-related cognitive decline, the inclusion criteria for the study expressly included subjects with mild to moderate dementia, and the protocol stated that one outcome of the study was to provide subjects with some improvement in their cognitive status. The outcome assessments for Protocol Pro-040-Plasm-01 included various validated neurocognitive assessments at baseline, and at follow-up visits at months one through five after baseline. These outcome assessments included the Standardized 25-foot Timed Gait Test, the Nine Hole Pegboard Test, the Montreal Cognitive Assessment, and the Quick Dementia Rating Scale, all of which are instruments used to assess neurocognitive status. Therefore, Protocol Pro-040-Plasm-01 collected study data to assess the effect of ProdromeNeuro™ Oil on cognitive status – as measured by changes in gait and changes in the severity of dementia, as determined by cognitive and functional abilities – of individuals with mild to moderate dementia.\u003C\u002Fp>\u003Cp>Whether an investigational article is a drug depends on the intent of the investigation. Based on the study design of Protocol Pro-040-Plasm-01, the investigational product, ProdromeNeuro™ Oil, as used in the clinical investigation, was a drug as defined in section 201(g)(1) of the FD&amp;C Act, because ProdromeNeuro™ Oil was studied for use in the treatment of mild to moderate dementia.\u003C\u002Fp>\u003Cp>Thus, before initiating the clinical investigation of ProdromeNeuro™ Oil conducted under Protocol Pro-040-Plasm-01, under 21 CFR 312.40, Prodrome Sciences was required to submit an IND to FDA and to have an IND in effect. FDA’s records indicate that Prodrome Sciences failed to submit an IND before conducting Protocol Pro-040-Plasm-01, in which 29 human subjects were enrolled and received investigational drug between July 2020 and March 2021.\u003C\u002Fp>\u003Cp>In your January 23 and January 31, 2025, written responses, you stated that Prodrome Sciences has hired a consulting partner to assist with remediation and resolution of the Form FDA 483 observation, and to provide ongoing FDA compliance support.\u003C\u002Fp>\u003Cp>In your written responses, you also outlined a corrective and preventive action plan that includes the following: (1) a comprehensive review of standard operating procedures and training programs to identify and address gaps; (2) employee training overseen by your consulting partner on the FDA requirements for dietary supplements, and the differences between clinical studies involving dietary supplements and clinical studies involving investigational drugs; and (3) regular audits conducted by your consulting partner to monitor the effectiveness of these actions.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions you have taken and plan to take, your written response is inadequate because your corrective action plan did not include sufficient information to address how Prodrome Sciences, as a sponsor, will prevent similar violations in the future. For example, your response does not include sufficient details on how Prodrome Sciences, as a sponsor, will determine whether IND regulations apply to future clinical investigations of products regulated by FDA, as required under 21 CFR part 312.2(a). Additionally, your corrective and preventive action plan does not include sufficient details about developing and implementing procedures to comply with IND regulations, if Prodrome Sciences should decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Prodrome Sciences will comply with IND regulations in the future.\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible to comply with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation; and it is Prodrome Sciences’ responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Prodrome Sciences’ failure to submit, and to have in effect, an IND before initiating Protocol Pro-040-Plasm-01 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Protocol Pro-040-Plasm-01 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must, among other things, be lawfully marketed in the United States as a drug product. As stated during the inspection and in your January 31, 2025, written response, ProdromeNeuro™ Oil is marketed as a dietary supplement, not as a drug product.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-01-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDayan B. Goodenowe, Ph.D.\n\nRecipient Title\n\nCEO\n\nProdrome Sciences USA, LLC\n\n27518 Via Industria\n\nTemecula, CA 92590\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDear Dr. Goodenowe:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between December 17, 2024, and January 10, 2025. The investigator representing FDA reviewed the role of Prodrome Sciences USA, LLC (Prodrome Sciences) as the sponsor of a clinical investigation (Protocol Pro‐040‐Plasm‐01, “ProdromeNeuro: An Open-Label Study of Omega 3 Oil Nutritional Supplementation for Aging-Related Cognitive Decline”) of the investigational drug ProdromeNeuro™ Oil (Omega-3 Plasmalogens).\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your written responses to the Form FDA 483, dated January 23 and January 31, 2025.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated January 23 and January 31, 2025, it appears that Prodrome Sciences did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312) governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\nYou failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\nFDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20 and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2.1 Prodrome Sciences failed to comply with these requirements. Specifically, Prodrome Sciences initiated and conducted Protocol Pro‐040‐Plasm‐01, a clinical investigation of the investigational drug ProdromeNeuro™ Oil, subject to section 505 of the FD&C Act [21 U.S.C. 355], without submitting and having in effect an IND.\nIn Prodrome Sciences’ January 31, 2025, written response to the Form FDA 483, you indicated that the objective of Protocol Pro‐040‐Plasm‐01 was to evaluate the safety and tolerability of ProdromeNeuro™ Oil as a nutritional supplement. Additionally, during the inspection you stated that the investigational product, ProdromeNeuro™ Oil, is a blend of naturally occurring alkylglycerols composed of docosahexaenoic acid (DHA) [22:6], docosapentaenoic acid (DPA) [22:5], and eicosapentaenoic acid (EPA) [20:5] fatty acids. You further stated that these dietary alkylglycerols are found naturally in shark liver oil, which makes ProdromeNeuro™ Oil a dietary supplement that does not require an IND.\nFor the reasons described below, we conclude that the evidence collected during the inspection shows that ProdromeNeuro™ Oil was intended for use as a drug, not as a dietary supplement, for the clinical investigation conducted under Protocol Pro‐040‐Plasm‐01. Therefore, Prodrome Sciences was required to submit an IND before conducting the clinical investigation.\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease….” Although Protocol Pro-040-Plasm-01 stated that the primary objective was to evaluate the safety and tolerability of ProdromeNeuro™ Oil in subjects with age-related cognitive decline, the inclusion criteria for the study expressly included subjects with mild to moderate dementia, and the protocol stated that one outcome of the study was to provide subjects with some improvement in their cognitive status. The outcome assessments for Protocol Pro-040-Plasm-01 included various validated neurocognitive assessments at baseline, and at follow-up visits at months one through five after baseline. These outcome assessments included the Standardized 25-foot Timed Gait Test, the Nine Hole Pegboard Test, the Montreal Cognitive Assessment, and the Quick Dementia Rating Scale, all of which are instruments used to assess neurocognitive status. Therefore, Protocol Pro-040-Plasm-01 collected study data to assess the effect of ProdromeNeuro™ Oil on cognitive status – as measured by changes in gait and changes in the severity of dementia, as determined by cognitive and functional abilities – of individuals with mild to moderate dementia.\nWhether an investigational article is a drug depends on the intent of the investigation. Based on the study design of Protocol Pro-040-Plasm-01, the investigational product, ProdromeNeuro™ Oil, as used in the clinical investigation, was a drug as defined in section 201(g)(1) of the FD&C Act, because ProdromeNeuro™ Oil was studied for use in the treatment of mild to moderate dementia.\nThus, before initiating the clinical investigation of ProdromeNeuro™ Oil conducted under Protocol Pro-040-Plasm-01, under 21 CFR 312.40, Prodrome Sciences was required to submit an IND to FDA and to have an IND in effect. FDA’s records indicate that Prodrome Sciences failed to submit an IND before conducting Protocol Pro-040-Plasm-01, in which 29 human subjects were enrolled and received investigational drug between July 2020 and March 2021.\nIn your January 23 and January 31, 2025, written responses, you stated that Prodrome Sciences has hired a consulting partner to assist with remediation and resolution of the Form FDA 483 observation, and to provide ongoing FDA compliance support.\nIn your written responses, you also outlined a corrective and preventive action plan that includes the following: (1) a comprehensive review of standard operating procedures and training programs to identify and address gaps; (2) employee training overseen by your consulting partner on the FDA requirements for dietary supplements, and the differences between clinical studies involving dietary supplements and clinical studies involving investigational drugs; and (3) regular audits conducted by your consulting partner to monitor the effectiveness of these actions.\nWhile we acknowledge the corrective and preventive actions you have taken and plan to take, your written response is inadequate because your corrective action plan did not include sufficient information to address how Prodrome Sciences, as a sponsor, will prevent similar violations in the future. For example, your response does not include sufficient details on how Prodrome Sciences, as a sponsor, will determine whether IND regulations apply to future clinical investigations of products regulated by FDA, as required under 21 CFR part 312.2(a). Additionally, your corrective and preventive action plan does not include sufficient details about developing and implementing procedures to comply with IND regulations, if Prodrome Sciences should decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Prodrome Sciences will comply with IND regulations in the future.\nAs a sponsor, you are responsible to comply with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation; and it is Prodrome Sciences’ responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Prodrome Sciences’ failure to submit, and to have in effect, an IND before initiating Protocol Pro-040-Plasm-01 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\nYour written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely yours,\n\u002FS\u002F\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________________\n1 Protocol Pro-040-Plasm-01 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must, among other things, be lawfully marketed in the United States as a drug product. As stated during the inspection and in your January 31, 2025, written response, ProdromeNeuro™ Oil is marketed as a dietary supplement, not as a drug product.","Prodrome Sciences USA, LLC","prodrome-sciences-usa-llc-717959-01082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodrome-sciences-usa-llc-717959-01082026","2026-10-26T08:09:44.574717+00:00","2026-01-20","717959","Dayan B. Goodenowe, Ph.D.","2026-08-19T07:17:30.103+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","26-HFD-45-01-01","2026-01-08",{"id":272,"raw":273,"subject":277,"body_html":279,"body_text":280,"firm_name":281,"letter_id":282,"created_at":186,"fei_number":19,"letter_url":283,"updated_at":284,"action_type":22,"case_status":285,"posted_date":246,"marcs_cms_no":286,"product_type":169,"closeout_date":287,"issuing_office":276,"recipient_name":288,"body_fetched_at":289,"delivery_method":290,"recipient_title":19,"reference_number":19,"action_taken_date":291,"medical_device_id":19,"response_letter_date":19},2421,[237,274,275,276,277,13,278,13],"\u003Ctime datetime=\"2022-09-23T04:00:00Z\">09\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmuscle-sports-products-llc-625731-09232022\">Muscle Sports Products, LLC\u003C\u002Fa>","Office of Human and Animal Food Operations East – Division 1","Unapproved New Drugs\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmuscle-sports-products-llc-625731-07262023\">\u003Ctime datetime=\"2023-08-01T04:00:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason R. Mancuso\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Muscle Sports Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>101 Dominion Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ronkonkoma\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11779\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto: jmancuso@customnutra.fit\">  jmancuso@customnutra.fit\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations East – Division 1\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\n\u003Cstrong>CMS # 625731\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Mancuso:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at www.musclesport.com, www.purgesports.com, www.musclemilitia.com, www.kodiaksupps.com, and your social media website at https:\u002F\u002Fwww. facebook.com\u002FOptituneNutrition\u002F in May 2022 and September 2022. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act through links on FDA’s website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-and-cosmetic-act-fdc-act\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-and-cosmetic-act-fdc-act\u003C\u002Fa> and the FDA regulations at \u003Ca href=\"https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21\">https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at www.musclesport.com in May 2022 and September 2022 and has determined that you take orders there for the products CardioBurn For Her Powder, Rhino Rampage Capsules™, Joint Revolution™ Capsules, STRESS B-COMPLEX, IMMUNITY + Powder, and Apple Cider Vinegar Capsules. The claims on this website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. In addition, we observed that your product IMMUNITY + Powder is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On the product webpage for CardioBurn For Her Powder, a product containing green coffee extract (https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Fher-series\u002Fproducts\u002Fcardioburn-for-her):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Green coffee extract . . . is a concentrated source of chlorogenic acid, a compound that may be able to reduce blood sugar and have an anti-diabetic effect. Green coffee bean extract may also be a potent . . .anti-obesity supplement.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the product webpage for Rhino Rampage PUMPED Capsules™, a product containing niacin (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Frhino-rampage-pumped-capsules):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Niacin has long been used to increase high-density lipoprotein (HDL), or the ‘good,’ cholesterol. HDL cholesterol helps sweep up low-density lipoprotein (LDL), or the ’bad,’ cholesterol, in your bloodstream.”\u003C\u002Fli>\n\t\u003Cli>“Blond et al. discovered in 20 men without diabetes but with dyslipidemia, 2g niacin supplementation over the course of eight weeks promoted a reduction in triglycerides (28%) and VLDL (68%) while increasing HDL cholesterol (17%).”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the product webpage for Joint Revolution™ Capsules (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Fjoint-revolution):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“May alleviate joint pain, reduce joint stiffness, and decrease the symptoms of common joint conditions”\u003C\u002Fli>\n\t\u003Cli>“Decreases swelling and inflammatory cytokines in soft tissue and joints”\u003C\u002Fli>\n\t\u003Cli>Claims about ingredients in the product\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “Glucosamine Sulfate . . . may also assist with the slowing down of joint damage.”\u003Cbr>\n&nbsp; &nbsp; o “Chondroitin Sulfate – May help with relieving joint pain, stiffness, and other joint symptoms.”\u003Cbr>\n&nbsp; &nbsp; o “MSM – Assists with . . . reducing joint stiffness and swelling.”\u003Cbr>\n&nbsp; &nbsp; o “Bromelain – Decreases swelling and inflammation in soft tissue and joint disorders. Also, the combination of bromelain and glucosamine provides relief from joint stiffness.”\u003Cbr>\n&nbsp; &nbsp; o “Glucosamine with the combination of chondroitin has shown to assist with pain relief in association with arthritis.”\u003Cbr>\n&nbsp; &nbsp; o “Chondroitin may help joint pain, improve joint stiffness, and decrease the symptoms of osteoarthritis.”\u003Cbr>\n&nbsp; &nbsp; o “Hyaluronic Acid . . . may also help decrease symptoms of osteoarthritis.”\u003Cbr>\n&nbsp; &nbsp; o “MSM . . . A recent study in Japan on rats . . . in an accepted human osteoarthritis model showed decreased degeneration of cartilage at the joint surface in the knee joints”\u003Cbr>\n&nbsp; &nbsp; o Under the heading “ANTI-INFLAMMATORY COMPLEX”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp; &nbsp; ▪“Quercetin . . . possesses anti-inflammatory . . . properties.”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; ▪“The combination of bromelain and glucosamine provides relief from joint stiffness. Studies have shown that bromelain may decrease swelling and inflammation in soft tissue and joint disorders. It has been used as an alternative treatment to NSAIDs for osteoarthritis.”\u003C\u002Fp>\n\n\u003Cp>On the product webpage for STRESS B-COMPLEX Capsules (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Fstress-b-complex):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Added choline &amp; inositol . . . help with regulating insulin levels”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your social media site at https:\u002F\u002Fwww.facebook.com\u002FOptituneNutrition\u002F, which directs consumers to your website www.musclesport.com to purchase your products:\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>IMMUNITY + Powder:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>From a post dated March 7, 2020 –\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “Boost your immune system to reduce your chances of getting infected during the cold and flu season. Did you know that elderberry prevents virus’ [sic] from being able to enter human cells thus preventing infection. With all the concern about the #coronavirus make sure your immune system is #optituned with Immunity + by Optitune! . . . #coldandfluseason”\u003Cbr>\n&nbsp; &nbsp; o “CORONAVIRUS OUTBREAK SUPPLEMENTING WITH IMMUNITY+ . . . Supplementing with Immunity+ can help you strengthen your immune system, speed up illness recovery, &amp;decrease the risk of infection. Stay protected, and choose a supplement that actually works.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>From a post dated May 20, 2020 describing ingredients in the product –“VITAMIN C – 1,000MG . . .\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Reduces upper respiratory tract infection”\u003Cbr>\n“VITAMIN D – 2,000IU\u003Cbr>\n&nbsp; &nbsp; o Improves macrophage (cells which ‘eat’ pathogens …)\u003Cbr>\n&nbsp; &nbsp; o Reduces symptoms of autoimmune dysfunction”\u003Cbr>\n“ZINC-50MG . . .\u003Cbr>\n&nbsp; &nbsp; o Reduces duration &amp; severity of common cold symptoms.”\u003Cbr>\n“ELDERBERRY – 750MG . . .\u003Cbr>\n&nbsp; &nbsp; o relieves symptoms of influenza an average of 4 days faster than placebo.\u003Cbr>\n&nbsp; &nbsp; o Helps fight bacteria.”\u003Cbr>\n“OLIVE LEAF EXTRACT – 400MG\u003Cbr>\n&nbsp; &nbsp; o Possesses antiviral effects\u003Cbr>\n&nbsp; &nbsp; o May be antibacterial against Staph infections.”\u003Cbr>\n“L-LYSINE-300MG\u003Cbr>\n&nbsp; &nbsp; o Shown promise in combatting certain types of infections. . . .\u003Cbr>\n&nbsp; &nbsp; o May be effective at reducing the severity of herpes flare ups.”\u003Cbr>\n“ECHINACEA-250MG\u003Cbr>\n&nbsp; &nbsp; o Helps accelerate recovery at the first sign of sickness.\u003Cbr>\n&nbsp; &nbsp; o Helps reduce the duration of sickness.\u003Cbr>\n&nbsp; &nbsp; o May help fight pathogens by stimulating macrophage production.”\u003C\u002Fp>\n\n\u003Cp>Apple Cider Vinegar Capsules:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>From a post dated April 28, 2020 – “Supplementing with 550mg of apple cider vinegar may help kill bacteria, lower blood sugar levels . . . .”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>FDA reviewed your website at www.purgesports.com in May 2022 and September 2022 and has determined that you take orders there for the products THERMX™ Powder and HYPEX Powder. The claims on this website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On the product webpage for THERMX™ Powder, a product containing chromium (https:\u002F\u002Fpurgesports.com\u002Fcollections\u002Fpurge-products\u002Fproducts\u002Fthermx#ingredients):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Chromium is an essential mineral with a role in insulin regulation and glucose management. It affects chromodulin, which improves its ability to enhance insulin receptor activity.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the product webpage for HYPEX Powder under “Ingredient Profile” (https:\u002F\u002Fpurgesports.com\u002Fcollections\u002Fpurge-products\u002Fproducts\u002Fhypex#ingredient-profile):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Citrulline Malate . . . converts to nitric oxide. Nitric oxide is a vasodilator that can help to lower blood pressure . . . .”\u003C\u002Fli>\n\t\u003Cli>“Kanna . . .\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Inhibits phosphodiesterase 4 in the amygdala to exert anti depressive effects.\u003Cbr>\n&nbsp; &nbsp; o Has been noted to have powerful reductions in anxiety.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Rauwolfia Vomitoria is a plant found in Africa that has been used in traditional medicine for heart, cancer, and brain ailments.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o May reduce blood pressure and blood sugar.\u003Cbr>\n&nbsp; &nbsp; o Has been noted to reduce psychosis”\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at https:\u002F\u002Fwww.musclemilitia.com\u002F in May 2022 and September 2022 and has determined that you take orders there for the product RECOMP Capsules. The claims on this website establish that the product is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>On the product webpage for RECOMP Capsules (https:\u002F\u002Fwww.musclemilitia.com\u002Fproducts\u002Frecomp):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Fenugreek [an ingredient in the product] helps . . . manage blood sugar”\u003C\u002Fli>\n\t\u003Cli>“Fenugreek . . .\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Decreases blood glucose”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Berberine [an ingredient in the product] . . .\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Potent blood glucose, cholesterol . . . reducing abilities”\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at www.kodiaksupps.com, which redirects to https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Falpha-series, in May 2022 and September 2022 and has determined that you take orders there for the products Attack™ Pre-Workout Powder and Coma™ Sleep &amp; Recovery Activator Lemon Drop Powder. The claims on this website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Attack™ Pre-Workout Powder under “Ingredient Profile” (https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Falpha-series\u002Fproducts\u002Fattack-pre-workout):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Citrulline Malate . . . converts to nitric oxide. Nitric oxide is a vasodilator that can help to lower blood pressure . . . .”\u003C\u002Fli>\n\t\u003Cli>“Arginine . . . has been studied for healing wounds . . . and preventing tissue degradation in people with critical illnesses.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the product webpage for Coma™ Sleep &amp; Recovery Activator Lemon Drop Powder under “Ingredient Profile” (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Fcoma-sleep-aid):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Reductions in glycine receptor stimulation or function . . . promote REM sleep behavior disorder.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products CardioBurn For Her Powder, IMMUNITY + Powder, and HYPEX Powder are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, CardioBurn For Her Powder, IMMUNITY + Powder, and HYPEX Powder fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comment:\u003C\u002Fp>\n\n\u003Cp>The Supplement Facts panel of your product RECOMP Capsules declares Bitter Orange Extract (Citrus aurantium) (see musclemilitia.com\u002Fproducts\u002Frecomp under Supplement Facts tab), and your product webpage for the RECOMP Capsules states, “Bitter orange extract contains neuroactive agents, synephrine, hordenine, and octopamine” (musclemilitia.com\u002Fproducts\u002Frecomp under “Ingredients” tab). Your website does not provide enough information for us to determine whether hordenine and octopamine have been added to RECOMP Capsules as ingredients or are present in trace amounts as components of Bitter Orange Extract. We also do not know whether these compounds are present in their original biogenic form or as synthetically produced salts (e.g., hordenine HCl).\u003Cbr>\n\u003Cbr>\nFDA recently sent warning letters to several firms selling dietary supplements containing hordenine, hordenine HCl, or octopamine as ingredients. See “FDA Sends Warning Letters to Multiple Companies for Illegally Selling Adulterated Dietary Supplements” and May 4, 2022 warning letters to, e.g., Ironmag Labs (hordenine) and Max Muscle (hordenine HCl and octopamine). Although FDA does not have enough information at present about the composition of RECOMP Capsules to take a position on whether the product is adulterated because of the presence of hordenine and octopamine, it is your responsibility to take any action necessary to ensure that your distribution and sale of RECOMP Capsules does not violate the Act, including evaluating whether the product contains any substances that render it adulterated.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email atLillian.aveta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ronald M. Pace\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast – Division 1\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described in the body of this letter, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The Facebook page refers consumers to the Internet address www.optitunenutrition.com, which redirects to https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Fgeneral-health.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJason R. Mancuso\n\nRecipient Title\n\nCEO\n\nMuscle Sports Products, LLC\n\n101 Dominion Blvd.\n\nRonkonkoma, NY 11779\n\nUnited States\n\njmancuso@customnutra.fit\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations East – Division 1\n\nUnited States\n\nWARNING LETTER\n\nCMS # 625731\n\nDear Mr. Mancuso:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at www.musclesport.com, www.purgesports.com, www.musclemilitia.com, www.kodiaksupps.com, and your social media website at https:\u002F\u002Fwww. facebook.com\u002FOptituneNutrition\u002F in May 2022 and September 2022. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act through links on FDA’s website at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-and-cosmetic-act-fdc-act and the FDA regulations at https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website at www.musclesport.com in May 2022 and September 2022 and has determined that you take orders there for the products CardioBurn For Her Powder, Rhino Rampage Capsules™, Joint Revolution™ Capsules, STRESS B-COMPLEX, IMMUNITY + Powder, and Apple Cider Vinegar Capsules. The claims on this website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. In addition, we observed that your product IMMUNITY + Powder is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn the product webpage for CardioBurn For Her Powder, a product containing green coffee extract (https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Fher-series\u002Fproducts\u002Fcardioburn-for-her):\n\n“Green coffee extract . . . is a concentrated source of chlorogenic acid, a compound that may be able to reduce blood sugar and have an anti-diabetic effect. Green coffee bean extract may also be a potent . . .anti-obesity supplement.”\n\nOn the product webpage for Rhino Rampage PUMPED Capsules™, a product containing niacin (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Frhino-rampage-pumped-capsules):\n\n“Niacin has long been used to increase high-density lipoprotein (HDL), or the ‘good,’ cholesterol. HDL cholesterol helps sweep up low-density lipoprotein (LDL), or the ’bad,’ cholesterol, in your bloodstream.”\n\n“Blond et al. discovered in 20 men without diabetes but with dyslipidemia, 2g niacin supplementation over the course of eight weeks promoted a reduction in triglycerides (28%) and VLDL (68%) while increasing HDL cholesterol (17%).”\n\nOn the product webpage for Joint Revolution™ Capsules (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Fjoint-revolution):\n\n“May alleviate joint pain, reduce joint stiffness, and decrease the symptoms of common joint conditions”\n\n“Decreases swelling and inflammatory cytokines in soft tissue and joints”\n\nClaims about ingredients in the product\n\no “Glucosamine Sulfate . . . may also assist with the slowing down of joint damage.”\n\no “Chondroitin Sulfate – May help with relieving joint pain, stiffness, and other joint symptoms.”\n\no “MSM – Assists with . . . reducing joint stiffness and swelling.”\n\no “Bromelain – Decreases swelling and inflammation in soft tissue and joint disorders. Also, the combination of bromelain and glucosamine provides relief from joint stiffness.”\n\no “Glucosamine with the combination of chondroitin has shown to assist with pain relief in association with arthritis.”\n\no “Chondroitin may help joint pain, improve joint stiffness, and decrease the symptoms of osteoarthritis.”\n\no “Hyaluronic Acid . . . may also help decrease symptoms of osteoarthritis.”\n\no “MSM . . . A recent study in Japan on rats . . . in an accepted human osteoarthritis model showed decreased degeneration of cartilage at the joint surface in the knee joints”\n\no Under the heading “ANTI-INFLAMMATORY COMPLEX”:\n\n▪“Quercetin . . . possesses anti-inflammatory . . . properties.”\n\n▪“The combination of bromelain and glucosamine provides relief from joint stiffness. Studies have shown that bromelain may decrease swelling and inflammation in soft tissue and joint disorders. It has been used as an alternative treatment to NSAIDs for osteoarthritis.”\n\nOn the product webpage for STRESS B-COMPLEX Capsules (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Fstress-b-complex):\n\n“Added choline & inositol . . . help with regulating insulin levels”\n\nOn your social media site at https:\u002F\u002Fwww.facebook.com\u002FOptituneNutrition\u002F, which directs consumers to your website www.musclesport.com to purchase your products:2\n\nIMMUNITY + Powder:\n\nFrom a post dated March 7, 2020 –\n\no “Boost your immune system to reduce your chances of getting infected during the cold and flu season. Did you know that elderberry prevents virus’ [sic] from being able to enter human cells thus preventing infection. With all the concern about the #coronavirus make sure your immune system is #optituned with Immunity + by Optitune! . . . #coldandfluseason”\n\no “CORONAVIRUS OUTBREAK SUPPLEMENTING WITH IMMUNITY+ . . . Supplementing with Immunity+ can help you strengthen your immune system, speed up illness recovery, &decrease the risk of infection. Stay protected, and choose a supplement that actually works.”\n\nFrom a post dated May 20, 2020 describing ingredients in the product –“VITAMIN C – 1,000MG . . .\n\no Reduces upper respiratory tract infection”\n\n“VITAMIN D – 2,000IU\n\no Improves macrophage (cells which ‘eat’ pathogens …)\n\no Reduces symptoms of autoimmune dysfunction”\n\n“ZINC-50MG . . .\n\no Reduces duration & severity of common cold symptoms.”\n\n“ELDERBERRY – 750MG . . .\n\no relieves symptoms of influenza an average of 4 days faster than placebo.\n\no Helps fight bacteria.”\n\n“OLIVE LEAF EXTRACT – 400MG\n\no Possesses antiviral effects\n\no May be antibacterial against Staph infections.”\n\n“L-LYSINE-300MG\n\no Shown promise in combatting certain types of infections. . . .\n\no May be effective at reducing the severity of herpes flare ups.”\n\n“ECHINACEA-250MG\n\no Helps accelerate recovery at the first sign of sickness.\n\no Helps reduce the duration of sickness.\n\no May help fight pathogens by stimulating macrophage production.”\n\nApple Cider Vinegar Capsules:\n\nFrom a post dated April 28, 2020 – “Supplementing with 550mg of apple cider vinegar may help kill bacteria, lower blood sugar levels . . . .”\n\nFDA reviewed your website at www.purgesports.com in May 2022 and September 2022 and has determined that you take orders there for the products THERMX™ Powder and HYPEX Powder. The claims on this website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn the product webpage for THERMX™ Powder, a product containing chromium (https:\u002F\u002Fpurgesports.com\u002Fcollections\u002Fpurge-products\u002Fproducts\u002Fthermx#ingredients):\n\n“Chromium is an essential mineral with a role in insulin regulation and glucose management. It affects chromodulin, which improves its ability to enhance insulin receptor activity.”\n\nOn the product webpage for HYPEX Powder under “Ingredient Profile” (https:\u002F\u002Fpurgesports.com\u002Fcollections\u002Fpurge-products\u002Fproducts\u002Fhypex#ingredient-profile):\n\n“Citrulline Malate . . . converts to nitric oxide. Nitric oxide is a vasodilator that can help to lower blood pressure . . . .”\n\n“Kanna . . .\n\no Inhibits phosphodiesterase 4 in the amygdala to exert anti depressive effects.\n\no Has been noted to have powerful reductions in anxiety.”\n\n“Rauwolfia Vomitoria is a plant found in Africa that has been used in traditional medicine for heart, cancer, and brain ailments.\n\no May reduce blood pressure and blood sugar.\n\no Has been noted to reduce psychosis”\n\nFDA reviewed your website at https:\u002F\u002Fwww.musclemilitia.com\u002F in May 2022 and September 2022 and has determined that you take orders there for the product RECOMP Capsules. The claims on this website establish that the product is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include:\n\nOn the product webpage for RECOMP Capsules (https:\u002F\u002Fwww.musclemilitia.com\u002Fproducts\u002Frecomp):\n\n“Fenugreek [an ingredient in the product] helps . . . manage blood sugar”\n\n“Fenugreek . . .\n\no Decreases blood glucose”\n\n“Berberine [an ingredient in the product] . . .\n\no Potent blood glucose, cholesterol . . . reducing abilities”\n\nFDA reviewed your website at www.kodiaksupps.com, which redirects to https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Falpha-series, in May 2022 and September 2022 and has determined that you take orders there for the products Attack™ Pre-Workout Powder and Coma™ Sleep & Recovery Activator Lemon Drop Powder. The claims on this website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn the product webpage for Attack™ Pre-Workout Powder under “Ingredient Profile” (https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Falpha-series\u002Fproducts\u002Fattack-pre-workout):\n\n“Citrulline Malate . . . converts to nitric oxide. Nitric oxide is a vasodilator that can help to lower blood pressure . . . .”\n\n“Arginine . . . has been studied for healing wounds . . . and preventing tissue degradation in people with critical illnesses.”\n\nOn the product webpage for Coma™ Sleep & Recovery Activator Lemon Drop Powder under “Ingredient Profile” (https:\u002F\u002Fmusclesport.com\u002Fproducts\u002Fcoma-sleep-aid):\n\n“Reductions in glycine receptor stimulation or function . . . promote REM sleep behavior disorder.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products CardioBurn For Her Powder, IMMUNITY + Powder, and HYPEX Powder are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, CardioBurn For Her Powder, IMMUNITY + Powder, and HYPEX Powder fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also offer the following comment:\n\nThe Supplement Facts panel of your product RECOMP Capsules declares Bitter Orange Extract (Citrus aurantium) (see musclemilitia.com\u002Fproducts\u002Frecomp under Supplement Facts tab), and your product webpage for the RECOMP Capsules states, “Bitter orange extract contains neuroactive agents, synephrine, hordenine, and octopamine” (musclemilitia.com\u002Fproducts\u002Frecomp under “Ingredients” tab). Your website does not provide enough information for us to determine whether hordenine and octopamine have been added to RECOMP Capsules as ingredients or are present in trace amounts as components of Bitter Orange Extract. We also do not know whether these compounds are present in their original biogenic form or as synthetically produced salts (e.g., hordenine HCl).\n\nFDA recently sent warning letters to several firms selling dietary supplements containing hordenine, hordenine HCl, or octopamine as ingredients. See “FDA Sends Warning Letters to Multiple Companies for Illegally Selling Adulterated Dietary Supplements” and May 4, 2022 warning letters to, e.g., Ironmag Labs (hordenine) and Max Muscle (hordenine HCl and octopamine). Although FDA does not have enough information at present about the composition of RECOMP Capsules to take a position on whether the product is adulterated because of the presence of hordenine and octopamine, it is your responsibility to take any action necessary to ensure that your distribution and sale of RECOMP Capsules does not violate the Act, including evaluating whether the product contains any substances that render it adulterated.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email atLillian.aveta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRonald M. Pace\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast – Division 1\n\n______________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described in the body of this letter, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\n2 The Facebook page refers consumers to the Internet address www.optitunenutrition.com, which redirects to https:\u002F\u002Fmusclesport.com\u002Fcollections\u002Fgeneral-health.","Muscle Sports Products, LLC","muscle-sports-products-llc-625731-09232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmuscle-sports-products-llc-625731-09232022","2026-10-26T08:09:28.727445+00:00","Closed Out","625731","2023-08-01","Jason R. Mancuso","2026-08-20T01:32:29.453+00:00","United Parcel Service","2022-09-23",{"id":293,"raw":294,"subject":79,"body_html":298,"body_text":299,"firm_name":300,"letter_id":301,"created_at":84,"fei_number":19,"letter_url":302,"updated_at":303,"action_type":22,"case_status":23,"posted_date":304,"marcs_cms_no":305,"product_type":110,"closeout_date":19,"issuing_office":100,"recipient_name":306,"body_fetched_at":307,"delivery_method":308,"recipient_title":19,"reference_number":309,"action_taken_date":310,"medical_device_id":19,"response_letter_date":19},4,[295,296,297,100,79,13,13,13],"\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-27T04:00:00Z\">07\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwoodbine-products-company-inc-729345-07272026\">Woodbine Products Company Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-107\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Stephen A. Kuzyk Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Secretary Treasurer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Woodbine Products Company Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>915 W. Smith Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Medina\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44256-2446\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-107\u003C\u002Fp>\u003Cp>July 27, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Kuzyk:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Woodbine Products Company Inc., FEI 1519202, at 915 W. Smith Road, Medina, from February 9 to 13, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 5, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> and ethanol-\u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., glycerin, propylene glycol, ethanol) used in the manufacture of your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Moreover, you used nonpharmaceutical-grade propylene glycol to manufacture your drug products.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of DEG or EG contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity before using it in manufacturing your OTC topical drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components includes a limit test in the United States Pharmacopoeia (USP) to ensure that the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ethanol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You manufacture multiple drugs that contain ethanol. You failed to adequately test your incoming component ethanol for methanol. Additionally, you failed to demonstrate that the component alcohol, used to manufacture your drug products, met USP monograph specifications including those for impurities (e.g., acetaldehyde, benzene). The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you tested retain samples of nine propylene glycol lots for DEG\u002FEG contamination and that samples of three lots were not available. You also state that in the future, you will conduct all USP identity and impurity tests for propylene glycol and glycerin. Your response is inadequate because you do not provide procedural controls to demonstrate adequate identification testing of your components. Also, your response does not investigate the use of nonpharmaceutical-grade components, nor does it evaluate the impact of improperly tested components to drug products on the market.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to the appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before their use in production to ensure that acceptable quality parameters are met.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of the adequacy of your supplier qualification program and its selection, qualification, and disqualification provisions. The review should include a corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol (ethanol), glycerin, propylene glycol, and certain additional high-risk components, we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains of all implicated finished drug product batches in which a retain of a high-risk drug component lot is unavailable for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination including, but not limited to, glycerin. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>For manufactured drug products within expiry, a commitment to provide, no later than 30 calendar days from the date of this letter, results from testing retains for all lots of alcohol components, including organic impurities. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately validate the processes used to manufacture your OTC drug products. You have not performed process performance qualification (PPQ) studies, nor do you have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality. Your firm also failed to validate your cleaning processes for non-dedicated equipment used to manufacture your OTC drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you will conduct cleaning validation on shared equipment and process validation on three batches of each drug formulation. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact of manufacturing with unvalidated processes, nor did you provide an action plan to address any drug product quality or safety risk for batches already distributed to the U.S. market.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>Furthermore, upon review of the inspectional records collected, it appears your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not suitable for its intended use. \u003Cstrong>(b)(4)\u003C\u002Fstrong> for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of microbiological contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for use in manufacturing operations.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for PPQ and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure that proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fli>\u003Cli>A risk assessment for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make their manufacturing equipment difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003C\u002Fli>\u003Cli>A description of the steps that will be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design, control, and maintenance to ensure the system design consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits. If gaps are identified, perform a risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to perform adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of adequate written responsibilities and procedures applicable to the QU and to follow such written procedures (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Establishment of laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>For each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fli>\u003Cli>Establishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you will implement QU procedures. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact to batches already distributed to the U.S. market without adequate QU oversight.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fli>\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1519202 and ATTN: Sena G. Dissmeyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-107\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Stephen A. Kuzyk Jr.\n\nRecipient Title\n\nSecretary Treasurer\n\nWoodbine Products Company Inc.\n\n915 W. Smith Road\n\nMedina, OH 44256-2446\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-107\nJuly 27, 2026\nDear Mr. Kuzyk:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Woodbine Products Company Inc., FEI 1519202, at 915 W. Smith Road, Medina, from February 9 to 13, 2026.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 5, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\nYour firm manufactures over-the-counter (OTC) (b)(4) drug products such as (b)(4) and ethanol-(b)(4). You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., glycerin, propylene glycol, ethanol) used in the manufacture of your OTC (b)(4) drug products. Moreover, you used nonpharmaceutical-grade propylene glycol to manufacture your drug products.\nProducts Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\nYou also failed to adequately test your incoming components at high risk of DEG or EG contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity before using it in manufacturing your OTC topical drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIdentity testing for glycerin and certain other high-risk drug components includes a limit test in the United States Pharmacopoeia (USP) to ensure that the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\nProducts Containing Ethanol\nYou manufacture multiple drugs that contain ethanol. You failed to adequately test your incoming component ethanol for methanol. Additionally, you failed to demonstrate that the component alcohol, used to manufacture your drug products, met USP monograph specifications including those for impurities (e.g., acetaldehyde, benzene). The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nIn your response, you state that you tested retain samples of nine propylene glycol lots for DEG\u002FEG contamination and that samples of three lots were not available. You also state that in the future, you will conduct all USP identity and impurity tests for propylene glycol and glycerin. Your response is inadequate because you do not provide procedural controls to demonstrate adequate identification testing of your components. Also, your response does not investigate the use of nonpharmaceutical-grade components, nor does it evaluate the impact of improperly tested components to drug products on the market.\nWithout adequate testing, you do not have scientific evidence that the components conform to the appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before their use in production to ensure that acceptable quality parameters are met.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of the adequacy of your supplier qualification program and its selection, qualification, and disqualification provisions. The review should include a corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol (ethanol), glycerin, propylene glycol, and certain additional high-risk components, we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains of all implicated finished drug product batches in which a retain of a high-risk drug component lot is unavailable for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination including, but not limited to, glycerin. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nFor manufactured drug products within expiry, a commitment to provide, no later than 30 calendar days from the date of this letter, results from testing retains for all lots of alcohol components, including organic impurities. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to adequately validate the processes used to manufacture your OTC drug products. You have not performed process performance qualification (PPQ) studies, nor do you have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality. Your firm also failed to validate your cleaning processes for non-dedicated equipment used to manufacture your OTC drug products.\nIn your response, you state that you will conduct cleaning validation on shared equipment and process validation on three batches of each drug formulation. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact of manufacturing with unvalidated processes, nor did you provide an action plan to address any drug product quality or safety risk for batches already distributed to the U.S. market.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nFurthermore, upon review of the inspectional records collected, it appears your (b)(4) is not suitable for its intended use. (b)(4) for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of microbiological contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of (b)(4) for use in manufacturing operations.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for PPQ and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\nA timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure that proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\nA risk assessment for the distributed drug products produced without performing any process validation studies.\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make their manufacturing equipment difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nA description of the steps that will be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nA comprehensive, independent assessment of your (b)(4) system design, control, and maintenance to ensure the system design consistently produces (b)(4) adhering to (b)(4) USP monograph specifications and appropriate microbial limits. If gaps are identified, perform a risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) failed to perform adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\nEstablishment of adequate written responsibilities and procedures applicable to the QU and to follow such written procedures (21 CFR 211.22(d)).\nEstablishment of laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nFor each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nEstablishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nEstablishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn your response, you state that you will implement QU procedures. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact to batches already distributed to the U.S. market without adequate QU oversight.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate.\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\nA complete and final review of each batch and its related information before the QU disposition decision.\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1519202 and ATTN: Sena G. Dissmeyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Woodbine Products Company Inc.","woodbine-products-company-inc-729345-07272026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwoodbine-products-company-inc-729345-07272026","2026-10-26T08:10:33.170942+00:00","2026-08-04","729345","Mr. Stephen A. Kuzyk Jr.","2026-08-19T04:27:37.449+00:00","VIA UPS","320-26-107","2026-07-27",{"id":312,"raw":313,"subject":79,"body_html":318,"body_text":319,"firm_name":320,"letter_id":321,"created_at":146,"fei_number":19,"letter_url":322,"updated_at":323,"action_type":22,"case_status":23,"posted_date":324,"marcs_cms_no":325,"product_type":212,"closeout_date":19,"issuing_office":317,"recipient_name":326,"body_fetched_at":327,"delivery_method":308,"recipient_title":19,"reference_number":19,"action_taken_date":328,"medical_device_id":19,"response_letter_date":19},2669,[314,315,316,317,79,13,13,13],"\u003Ctime datetime=\"2022-05-17T13:20:00Z\">05\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-10T04:00:00Z\">05\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolorful-products-corporation-624415-05102022\">Colorful Products Corporation\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Brian W. Davidson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Colorful Products Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2550 Azurite Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Newbury Park\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91320-1201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 10, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Davidson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Colorful Products Corporation, FEI 2083633, at 2550 Azurite Circle, from November 8 to November 17, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We have not received a response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and hand sanitizers\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Your Quality Unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Testing for the identity and strength of the active ingredients was performed and reviewed prior to release for each batch of drug product (21 CFR 211.165(a)).\u003C\u002Fli>\n\t\u003Cli>Thorough investigations for out-of-specifications (OOS) results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Appropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of appropriate annual product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\t\u003Cli>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o&nbsp; Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o&nbsp; A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fp>\n\n\u003Cp>&nbsp; An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fp>\n\n\u003Cp>&nbsp; A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o&nbsp; A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o&nbsp; Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; Stability-indicating methods.\u003Cbr>\n&nbsp; o&nbsp; Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>\n&nbsp; o&nbsp; An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>\n&nbsp; o&nbsp; Detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>\n&nbsp; o&nbsp; All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked appropriate process validation for your drug products. For example, you confirmed to our investigator that process validation was not performed for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> or hand sanitizer drug products. In addition, you also did not provide documentation or written procedures for performing process validation. You also confirmed that equipment qualification has not been performed on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water \u003Cstrong>(b)(4)\u003C\u002Fstrong> or on the equipment (e.g., mixing tanks, filling lines, and packaging lines) used to manufacture your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Validation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems (including analytical methods used by you and contract testing labs), quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing process performance qualification for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Your process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, and you failed to establish written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) &amp; (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture your OTC drug products and non-drug products. For example, our investigator observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You confirmed to our investigator that cleaning validation has not been performed for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Equipment Cleaning\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacks cleaning and maintenance procedures for your equipment used to manufacture your drug products. While you document the cleaning of your filling lines, you confirmed to our investigator that you do not document the cleaning of other equipment used to manufacture your drug products. In addition, you stated to our investigator that documentation of the filling lines’ cleaning only began in August 2021. Further, our investigator noted missing information for the filling lines' cleaning logs including product description, lot numbers, and cleaning and sanitization start and end times.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitization\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacks procedures on how to sanitize and maintain your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that you began sampling your water system in September 2021. Our review of your water system testing results, collected by our investigator, found total plate count (TPC) results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002FmL (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002FmL). You stated to our investigator that you resanitized the water system and resampled. Our review of the retest results only found the testing for total organic carbon (TOC). Your firm has not provided evidence that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is operating in a state of control. In addition, you could not provide a written investigation, including a description of your resanitization activities, a root cause for the elevated microbial results, or an appropriate CAPA.\u003C\u002Fp>\n\n\u003Cp>Inadequate removal of active ingredients and residues from manufacturing equipment during cleaning can result in cross-contamination of your drug products. Furthermore, inadequate cleaning and sanitization of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system can result in microbial contamination of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\n\t\u003Cli>Your plans regarding the manufacture of both pharmaceutical and nonpharmaceutical products at your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide your plan to separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; drugs with higher toxicities\u003Cbr>\n&nbsp; o&nbsp; drugs with higher drug potencies\u003Cbr>\n&nbsp; o&nbsp; drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o&nbsp; drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o&nbsp; swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o&nbsp; maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>A comprehensive independent assessment of your water system design, control, and maintenance, and corresponding CAPAs.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\u003C\u002Fli>\n\t\u003Cli>Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records. (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked controls to assure the integrity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacturing of your drug products. For example, your firm utilized software (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for the retention of data, including your drug product formulations and the quarantine and release status of drug products. This software is also used to document the completion of manufacturing steps on batch records, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> amounts, manufacturing activities, and calculations. You stated to our investigator that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> software was not validated and lacked audit trails.\u003C\u002Fp>\n\n\u003Cp>In addition, your firm lacked adequate controls to ensure that actions are attributed to authorized individuals with unique and unshared login credentials. For example, our investigator observed that the login credentials of employee, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were used to document the completion of several manufacturing activities on two drug product batch records dated March 17, 2021, and July 19, 2021. However, you stated to our investigator that \u003Cstrong>(b)(4)\u003C\u002Fstrong> has not been employed at the company since September 2019. Further, it was observed that login credentials including “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” were used to document the completion of several manufacturing activities. You stated to our investigator that these login credentials were shared by multiple employees. Shared login credentials are unacceptable, as this practice prevents the identification of specific individuals accessing a controlled system.\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a [drug] manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your responses with the unique identifier: \u003Cstrong>CMS 624415\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Santiago Gallardo Johnson, Acting Compliance Officer via email at, Santiago.GallardoJohnson@fda.hhs.gov or by telephone at 619-941-3760.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the&nbsp;Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Colorful Products Corporation hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Brian W. Davidson\n\nRecipient Title\n\nCEO\n\nColorful Products Corporation\n\n2550 Azurite Circle\n\nNewbury Park, CA 91320-1201\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nMay 10, 2022\n\nDear Mr. Davidson:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Colorful Products Corporation, FEI 2083633, at 2550 Azurite Circle, from November 8 to November 17, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe have not received a response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR211.22).\n\nYour firm manufactures over-the-counter (OTC) topical drug products such as (b)(4) and hand sanitizers1. Your Quality Unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\n\nTesting for the identity and strength of the active ingredients was performed and reviewed prior to release for each batch of drug product (21 CFR 211.165(a)).\n\nThorough investigations for out-of-specifications (OOS) results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\n\nAppropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\n\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\n\nPerformance of appropriate annual product reviews (21 CFR 211.180(e)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\n An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\n A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\n\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods.\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\n\no Detailed definition of the specific attributes to be tested at each station (timepoint).\n\no All procedures that describe these and other elements of your remediated stability program.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm lacked appropriate process validation for your drug products. For example, you confirmed to our investigator that process validation was not performed for your (b)(4) or hand sanitizer drug products. In addition, you also did not provide documentation or written procedures for performing process validation. You also confirmed that equipment qualification has not been performed on your (b)(4) water (b)(4) or on the equipment (e.g., mixing tanks, filling lines, and packaging lines) used to manufacture your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nProcess Validation\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems (including analytical methods used by you and contract testing labs), quality of input materials, and reliability of each manufacturing process step and control.\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing process performance qualification for each of your marketed drug products.\n\nYour process performance protocols, and written procedures for qualification of equipment and facilities.\n\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, and you failed to establish written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) & (b)).\n\nYou have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture your OTC drug products and non-drug products. For example, our investigator observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\n\nLack of Cleaning Validation\n\nYou confirmed to our investigator that cleaning validation has not been performed for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products.\n\nLack of Equipment Cleaning\n\nYour firm lacks cleaning and maintenance procedures for your equipment used to manufacture your drug products. While you document the cleaning of your filling lines, you confirmed to our investigator that you do not document the cleaning of other equipment used to manufacture your drug products. In addition, you stated to our investigator that documentation of the filling lines’ cleaning only began in August 2021. Further, our investigator noted missing information for the filling lines' cleaning logs including product description, lot numbers, and cleaning and sanitization start and end times.\n\nLack of (b)(4) Sanitization\n\nYour firm lacks procedures on how to sanitize and maintain your (b)(4). Your firm stated that you began sampling your water system in September 2021. Our review of your water system testing results, collected by our investigator, found total plate count (TPC) results of (b)(4) cfu\u002FmL ((b)(4) cfu\u002FmL). You stated to our investigator that you resanitized the water system and resampled. Our review of the retest results only found the testing for total organic carbon (TOC). Your firm has not provided evidence that your (b)(4) is operating in a state of control. In addition, you could not provide a written investigation, including a description of your resanitization activities, a root cause for the elevated microbial results, or an appropriate CAPA.\n\nInadequate removal of active ingredients and residues from manufacturing equipment during cleaning can result in cross-contamination of your drug products. Furthermore, inadequate cleaning and sanitization of your (b)(4) water system can result in microbial contamination of your drug products.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\nYour plans regarding the manufacture of both pharmaceutical and nonpharmaceutical products at your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide your plan to separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nA comprehensive independent assessment of your water system design, control, and maintenance, and corresponding CAPAs.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\n\nRegarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\n4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records. (21 CFR 211.68(b)).\n\nYour firm lacked controls to assure the integrity of (b)(4) used in the manufacturing of your drug products. For example, your firm utilized software (i.e., (b)(4)) for the retention of data, including your drug product formulations and the quarantine and release status of drug products. This software is also used to document the completion of manufacturing steps on batch records, including (b)(4) amounts, manufacturing activities, and calculations. You stated to our investigator that this (b)(4) software was not validated and lacked audit trails.\n\nIn addition, your firm lacked adequate controls to ensure that actions are attributed to authorized individuals with unique and unshared login credentials. For example, our investigator observed that the login credentials of employee, (b)(4), were used to document the completion of several manufacturing activities on two drug product batch records dated March 17, 2021, and July 19, 2021. However, you stated to our investigator that (b)(4) has not been employed at the company since September 2019. Further, it was observed that login credentials including “(b)(4)” and “(b)(4)” were used to document the completion of several manufacturing activities. You stated to our investigator that these login credentials were shared by multiple employees. Shared login credentials are unacceptable, as this practice prevents the identification of specific individuals accessing a controlled system.\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a [drug] manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your responses with the unique identifier: CMS 624415.\n\nIf you have questions regarding the contents of this letter, please contact Santiago Gallardo Johnson, Acting Compliance Officer via email at, Santiago.GallardoJohnson@fda.hhs.gov or by telephone at 619-941-3760.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n__________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Colorful Products Corporation hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&C Act.","Colorful Products Corporation","colorful-products-corporation-624415-05102022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolorful-products-corporation-624415-05102022","2026-10-26T08:08:17.023041+00:00","2022-05-17","624415","Mr. Brian W. Davidson","2026-08-20T01:53:42.803+00:00","2022-05-10",{"id":330,"raw":331,"subject":12,"body_html":337,"body_text":338,"firm_name":339,"letter_id":340,"created_at":146,"fei_number":19,"letter_url":341,"updated_at":342,"action_type":22,"case_status":285,"posted_date":343,"marcs_cms_no":344,"product_type":212,"closeout_date":345,"issuing_office":335,"recipient_name":346,"body_fetched_at":347,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":348,"medical_device_id":19,"response_letter_date":19},2640,[332,333,334,335,12,13,336,13],"\u003Ctime datetime=\"2022-05-31T13:20:00Z\">05\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-11T05:00:00Z\">03\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaj-food-products-inc-624051-03112022\">CAJ Food Products Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations East Division 6","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaj-food-products-inc-624051-08042022\">\u003Ctime datetime=\"2022-08-08T04:00:00Z\">08\u002F08\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Matt Herzog\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CAJ Food Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11650 Olio Rd. Suite 1000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fishers\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46037\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@drinkbeetjuice.com\"> info@drinkbeetjuice.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations East Division 6\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nFY22-HAFE6-05 CMS 624051\u003C\u002Fp>\n\n\u003Cp>March 11, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Herzog:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your Amazon.com storefronts at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FBiotta\u002Fpage\u002F9B960DEE-B174-4936-974D-A819B9769B6B?ref_=ast_bln and https:\u002F\u002Fwww.amazon.com\u002Fjuiceperformer?&amp;_encoding=UTF8&amp;tag=biottajuices-20&amp;linkCode=ur2&amp;linkId=d3d1183c057052af439e1da624875d15&amp;camp=1789&amp;creative=9325 in November – December 2021, and has determined that you take orders there for the products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice. We also reviewed your website at www.drinkbeetjuice.com, which directs consumers to your websites at www.biottajuices.com, and www.juiceperformer.com, both of which direct consumers to your Amazon.com storefronts to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Biotta product webpage claims\u003C\u002Fstrong>\u003Cbr>\n• Biotta Apple Beet Ginger Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fapple-beet-ginger-juice\u002F)\u003Cbr>\n- “Ginger: may … protect against Alzheimer’s”\u003Cbr>\n- “Helps fight cancer…Apple: reduces the risk of colon and lung cancer\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>…Beet: helps fight breast cancer, also protects from pancreatic, prostate cancers…Ginger: lowers the risk of breast, ovarian, pancreatic cancers”\u003Cbr>\n- “Apple: prevents chronic diseases … Beet: reduces blood pressure … Ginger: calms indigestion and reduces nausea”\u003C\u002Fp>\n\n\u003Cp>• Biotta Beet Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbeet-juice\u002F)\u003Cbr>\n- “Helps reduce blood pressure … Hypertension\u002FAHA study shows 7% reduction in blood pressure … Contributes to a reduction in arterial stiffness”\u003Cbr>\n- “…may lower risk of stroke…\u003Cbr>\n- “Improved mobility for patients with COPD [chronic obstructive pulmonary disease]… Improved muscle power in patients with heart failure”\u003Cbr>\n- “May help prevent Type 2 Diabetes”\u003Cbr>\n- “Powerful … anti-inflammatory”\u003C\u002Fp>\n\n\u003Cp>• Biotta Carrot Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcarrot-juice\u002F)\u003Cbr>\n- “Prevents … acne …”\u003Cbr>\n- “Lowers risk of cardiovascular disease”\u003Cbr>\n- “Reduces the risk of stroke”\u003Cbr>\n- “Reduces breast cancer risk…”\u003Cbr>\n- “When the liver functions well, it prevents the accumulation of fat and aids in its rapid digestion, preventing … obesity”\u003C\u002Fp>\n\n\u003Cp>• Biotta Elderberry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Felderberry-juice\u002F)\u003Cbr>\n- “[E]lderberry juice…has been effective in relieving colds and flu…”\u003Cbr>\n- “Treats respiratory illness…May help reduce swelling in mucous membranes…antiviral properties of elderberries were able to effectively inhibit the H1N1 virus, and offered similar effects to prescription medications like Tamiflu”\u003Cbr>\n- “Flavonoids in elderberries … may help prevent damage to the body’s cells … Lowers cholesterol …”\u003C\u002Fp>\n\n\u003Cp>• Biotta Golden Beet Juice Blend with Turmeric “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fgolden-beet-juice-blend-turmeric\u002F)\u003Cbr>\n- “Improves heart health…Reduces blood pressure…Stabilizes blood sugar…Assists in fighting against heart disease”\u003Cbr>\n- “Provides powerful anti-inflammatory effects … May be effective in lowering bad cholesterol”\u003C\u002Fp>\n\n\u003Cp>• Biotta Celery Root Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcelery-juice\u002F)\u003Cbr>\n- “Acts as a diuretic, helping neutralize pH balance and stimulating kidney function, ridding the body of toxins and allowing the body to resist disease … Reduces formation of kidney stones”\u003Cbr>\n- “Acts as an anti-inflammatory … Used to reduce effects of asthma”\u003C\u002Fp>\n\n\u003Cp>• Biotta Breuss Vegetable Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbreuss-vegetable-juice\u002F)\u003Cbr>\n- “Ideal for Breuss cancer treatment…”\u003Cbr>\n- “Featured in Dr. Breuss’ book – The Breuss Cancer Cure: Advice for the Prevention and Natural Treatment of Cancer, Leukemia, and Other Seemingly Incurable Diseases”\u003C\u002Fp>\n\n\u003Cp>• Biotta Tart Cherry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Ftart-cherry-juice\u002F)\u003Cbr>\n- “Ideal for reducing inflammation …”\u003Cbr>\n- “Prevents gout…Tart cherry juice can combat gout, a type of arthritis that causes repeated attacks of intense pain and swelling”\u003Cbr>\n- “Good source of Potassium … Consuming foods rich in potassium may help lower blood pressure and decrease the risk of kidney stones”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Juice Performer webpage claims\u003C\u002Fstrong>\u003Cbr>\nOn a page titled “Science” in the “Beet” section of the Juice Performer website (http:\u002F\u002Fwww.juiceperformer.com\u002Fbeet-performer\u002Fscience\u002F):\u003C\u002Fp>\n\n\u003Cp>Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice\u003Cbr>\n- “Beet juice also lowers blood pressure…and reduces inflammation in the body”\u003Cbr>\n- “Research has shown that a daily inorganic nitrate dose (like from Beet juice) can be as effective as medical intervention in reducing blood pressure… Some of the findings include:\u003Cbr>\n&nbsp; &nbsp;  Drinking 8 oz of Beet juice lowered systolic blood pressure by an average of 4-5 points\u003Cbr>\n&nbsp; &nbsp;  Beet juice contributed to a reduction in arterial stiffness as well as a sustained reduction in blood pressure. This was found to be as effective as prescription medication.\u003Cbr>\n&nbsp; &nbsp;  Seniors With Heart Failure Benefit From Beetroot Juice”\u003Cbr>\n- “Patients with COPD were able to improve their exercise function after drinking Beet juice.”\u003C\u002Fp>\n\n\u003Cp>Your Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: U.S. Food and Drug Administration, Alecia Marson-Acting Compliance Officer, 550 W. Jackson Blvd., Suite 1500 Chicago, IL 60661. If you should have any questions regarding any issue in this letter, please contact Alecia Marson, Acting Compliance Officer, at (414) 326-3973 or email Alecia.Marson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nDistrict Director | FDA Chicago District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations East Division 6\u003C\u002Fp>\n\n\u003Cp>____________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Here and throughout the remainder of the letter, citations have been removed where they appear on your website.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMatt Herzog\n\nRecipient Title\n\nPresident\n\nCAJ Food Products Inc.\n\n11650 Olio Rd. Suite 1000\n\nFishers, IN 46037\n\nUnited States\n\ninfo@drinkbeetjuice.com\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations East Division 6\n\nUnited States\n\nWARNING LETTER\n\nFY22-HAFE6-05 CMS 624051\n\nMarch 11, 2022\n\nDear Mr. Herzog:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your Amazon.com storefronts at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FBiotta\u002Fpage\u002F9B960DEE-B174-4936-974D-A819B9769B6B?ref_=ast_bln and https:\u002F\u002Fwww.amazon.com\u002Fjuiceperformer?&_encoding=UTF8&tag=biottajuices-20&linkCode=ur2&linkId=d3d1183c057052af439e1da624875d15&camp=1789&creative=9325 in November – December 2021, and has determined that you take orders there for the products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice. We also reviewed your website at www.drinkbeetjuice.com, which directs consumers to your websites at www.biottajuices.com, and www.juiceperformer.com, both of which direct consumers to your Amazon.com storefronts to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of website claims that provide evidence that your products are intended for use as drugs include:\n\nBiotta product webpage claims\n\n• Biotta Apple Beet Ginger Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fapple-beet-ginger-juice\u002F)\n\n- “Ginger: may … protect against Alzheimer’s”\n\n- “Helps fight cancer…Apple: reduces the risk of colon and lung cancer1…Beet: helps fight breast cancer, also protects from pancreatic, prostate cancers…Ginger: lowers the risk of breast, ovarian, pancreatic cancers”\n\n- “Apple: prevents chronic diseases … Beet: reduces blood pressure … Ginger: calms indigestion and reduces nausea”\n\n• Biotta Beet Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbeet-juice\u002F)\n\n- “Helps reduce blood pressure … Hypertension\u002FAHA study shows 7% reduction in blood pressure … Contributes to a reduction in arterial stiffness”\n\n- “…may lower risk of stroke…\n\n- “Improved mobility for patients with COPD [chronic obstructive pulmonary disease]… Improved muscle power in patients with heart failure”\n\n- “May help prevent Type 2 Diabetes”\n\n- “Powerful … anti-inflammatory”\n\n• Biotta Carrot Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcarrot-juice\u002F)\n\n- “Prevents … acne …”\n\n- “Lowers risk of cardiovascular disease”\n\n- “Reduces the risk of stroke”\n\n- “Reduces breast cancer risk…”\n\n- “When the liver functions well, it prevents the accumulation of fat and aids in its rapid digestion, preventing … obesity”\n\n• Biotta Elderberry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Felderberry-juice\u002F)\n\n- “[E]lderberry juice…has been effective in relieving colds and flu…”\n\n- “Treats respiratory illness…May help reduce swelling in mucous membranes…antiviral properties of elderberries were able to effectively inhibit the H1N1 virus, and offered similar effects to prescription medications like Tamiflu”\n\n- “Flavonoids in elderberries … may help prevent damage to the body’s cells … Lowers cholesterol …”\n\n• Biotta Golden Beet Juice Blend with Turmeric “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fgolden-beet-juice-blend-turmeric\u002F)\n\n- “Improves heart health…Reduces blood pressure…Stabilizes blood sugar…Assists in fighting against heart disease”\n\n- “Provides powerful anti-inflammatory effects … May be effective in lowering bad cholesterol”\n\n• Biotta Celery Root Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcelery-juice\u002F)\n\n- “Acts as a diuretic, helping neutralize pH balance and stimulating kidney function, ridding the body of toxins and allowing the body to resist disease … Reduces formation of kidney stones”\n\n- “Acts as an anti-inflammatory … Used to reduce effects of asthma”\n\n• Biotta Breuss Vegetable Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbreuss-vegetable-juice\u002F)\n\n- “Ideal for Breuss cancer treatment…”\n\n- “Featured in Dr. Breuss’ book – The Breuss Cancer Cure: Advice for the Prevention and Natural Treatment of Cancer, Leukemia, and Other Seemingly Incurable Diseases”\n\n• Biotta Tart Cherry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Ftart-cherry-juice\u002F)\n\n- “Ideal for reducing inflammation …”\n\n- “Prevents gout…Tart cherry juice can combat gout, a type of arthritis that causes repeated attacks of intense pain and swelling”\n\n- “Good source of Potassium … Consuming foods rich in potassium may help lower blood pressure and decrease the risk of kidney stones”\n\nJuice Performer webpage claims\n\nOn a page titled “Science” in the “Beet” section of the Juice Performer website (http:\u002F\u002Fwww.juiceperformer.com\u002Fbeet-performer\u002Fscience\u002F):\n\nJuice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice\n\n- “Beet juice also lowers blood pressure…and reduces inflammation in the body”\n\n- “Research has shown that a daily inorganic nitrate dose (like from Beet juice) can be as effective as medical intervention in reducing blood pressure… Some of the findings include:\n\n Drinking 8 oz of Beet juice lowered systolic blood pressure by an average of 4-5 points\n\n Beet juice contributed to a reduction in arterial stiffness as well as a sustained reduction in blood pressure. This was found to be as effective as prescription medication.\n\n Seniors With Heart Failure Benefit From Beetroot Juice”\n\n- “Patients with COPD were able to improve their exercise function after drinking Beet juice.”\n\nYour Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to the following address: U.S. Food and Drug Administration, Alecia Marson-Acting Compliance Officer, 550 W. Jackson Blvd., Suite 1500 Chicago, IL 60661. If you should have any questions regarding any issue in this letter, please contact Alecia Marson, Acting Compliance Officer, at (414) 326-3973 or email Alecia.Marson@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nDistrict Director | FDA Chicago District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations East Division 6\n\n____________________________________\n\n1 Here and throughout the remainder of the letter, citations have been removed where they appear on your website.","CAJ Food Products Inc.","caj-food-products-inc-624051-03112022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaj-food-products-inc-624051-03112022","2026-10-26T08:08:10.075522+00:00","2022-05-31","624051","2022-08-08","Matt Herzog","2026-08-20T01:51:26.479+00:00","2022-03-11",17,{"510k":351,"classification":352,"enforcement":353,"event":354,"event_backfill":355,"pma":356,"warning_letter":357},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]